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Objective 
In this study 
fixe.d 
Blood 
by nCUlVHQ.' 
Abstract 
optimum minimum time intervals and duration for testing novel 
\Jun.""'" drugs has been determined in 13 clinical trials. 
active constituents were determined in a manner that 
requirements for bioavailability and bioequivalence as set out 
Bioavailability of isoniazid, 
was determined 
Cmax, half-life, 
using the 
and to determine 90% CCIlDOlenc:;e mT<»ri'<O consideration Cmax, 
The Spearman coefficient verified the optimum reduced 
aSSOCl:atlCm of Cmax with AUCT, Cmax with AUCI and "n.I!\t-.. • ..... ~>rI 
with 
with '-'VJ:uv.u", ... 
disease status 
Results 
data set allowed comparison of individual r""t,"'r"",,,,,,,,, 
made possible comparisons of the uu., .... """"' ... 
subject number on pharmacokinetic outcomes. 
The UU\.uUJ'''''' show an optimum mtmmum time protocol of 6 time namely, 
0, 1, is sufficient for determining quality assurance for fixed 
already in the market. An 11 0, 0.25, 
0.5, 1, 1 4, 6 and 8 hours provided information and is 
time points. Comparison data set 
ritamp:icin yielded significantly of the 
principal compared with the same 
combination. mean Cmax values were significantly 
of formulation, in females C01TIOare:o 
volunteers attained significantly higher mean Cmax values 
lIruTI01ICm and 
","","'.,. Healthy 
rifampicin than did 
patients with tuberculosis. The minimum required number for 
a fixed-dose drug combination COllS1!;t1t1Ig of isoniazid, 
pyrazinamide was found to be 18 subjects. 
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Chapter 1 Introduction 
Chapter 1 
Introduction 
Tuberculosis is an· ancient human ..... ,,""""'" but efforts to 
illness control have been only For 
1 
reason, policy, 
intervention, management and discovery 
paramount importance. 
new treatments will remain of 
essential anti-tuberculosis drugs investigated in study were isoniazid, 
'ltatnplcm, pyrazinamide and ethambutol which are first-line drugs currently 
anti-tuberculosis treatment. 
History of Tuberculosis 
Tuberculosis is responsible for some of the greatest morbidity and mortality of all 
infectious ..... ",,,",,,,,,, that plague humans today. In ancient Hindu tuberculosis 
is r",Ti"rr~.rI to as Rogaraj, the king disease, and Rajayakshma, the '.U"~,u.",", of 
first of like John Bunyan's "£'n_+n'_ of all these Men of 
, emphasises that tuberculosis is still forefront of the disease burden. 
The name fact indiscriminately, 
affecting monarch and peasant 10,63, 131]. 
Tuberculosis surveillance in is inadequate for determining accurate 
burden TB is estimated indirectly 
measurements. measurements include average annual risk infection, 
reported incidence smear-positive QISleaSe, e:;;tmlate:d. cover of population by 
health estimated proportion all smear-positive cases, the case 
fatality rates for smear-positive and other forms [2, 171, 175]. 
1 
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The World Organisation estimates are as as 20 million 
actiye cases of tuberculosis worldwide. Active cases annually an estimated 
50':'100 million people in areas high prevalence. Approximately 3 million people 
of tuberculosis, more than 80% of whom developing die 
countries Q."'''",v ...... u for 25% of all avoidable deaths in 
developing countries, and 75% of these cases occur m who are 
economically productive 18,21, 163]. 
For tuberculosis is a dreaded deadly disease, reminiscent the CU~JlL"",,"'''' 
tuberculosis during the Industrial Revolution [10, 31, 168, 
Mycobacterium tuberculosis is the most 1TTI:nn,,.,,.n of the mVCOIJacten 
in human disease. However, a number other mycobacteria can produce 
pulmonary or other u.,,"' ... ,'''' in man indistinguishable from infection caused by 
Mycobacterium tuberculosis [1,60]. 
The the TB problem is enormous [ Its economic impact 
reflects the direct and indirect costs treatment and smloeCIe:u 
contact investigations, screening, preventative therapy programmes, hospital and 
control, cost of lost income, 
of (espedally for women), 
households [13, 32, 33, 127, 170,1 
2 
of employment, decreased likelihood 
creation orphans and one-parent 
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1.2 Treatment of Tuberculosis 
March 24th 1882 when Koch, describing series of 
that led to the discovery of the organism responsible for tuberculosis, concluded 
that, to control the U';:>''''~;:>'''' the sources from which infectious material 
must be closed as far as possible. The most important these sources, is the 
sputum of patients. This was a landmark in the chemotherapy of tuberculosis [11 > 
132]. 
Anti-tuberculosis drugs should ideally have properties: bactericidal ability, 
sterilising activity and prevention of resistance The susceptibility of 
mycobacterium depends on access of the drug to the site where it is needed and 
for treatment, it is necessary that the formulation is for 
[134}. Useful achieving efficient drug and concentration at 
of the would a pro-drug is converted to the form in the 
bacteria [2, 155]. The benefit a effective anti-tuberculosis or 
combination of should provide better therapy, lower cost and easy supply. 
objective of tuberculosis control is to mortality, morbidity, 
nrp'''PlnT relapse, and drug [133]. control at 
achieving standardised short-course chemotherapy (SCC) under direct observation, 
at least during initial of treatment, all smear-positive TB cases [6]. 
The success of directly observed treatment strategy (DOTS), in addressing the 
global tuberculosis emergency, on a five-point approach. This includes 
government commitment to a national tuberculosis adequate 
provision case detection, implementation of short-course 
chemotherapy, of essential drugs, and 
3 
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monitoring outcome [41, 130, 1 
A of anti-tuberculosis formulations is currently available. It is important 
that ensuring appropriate drug dose in combined formulation patient-weight should 
be considered, and that 
health care PEn,''''''''' 
training and experience of health care pel~sonm~l, the 
available resources should form part of the overall 
strategy care, and procurement drugs from a national list essential 
drugs [7]. 
The consequence taI1mne, war and natural ",Ui)"'i)""" is the of large 
populations of displaced, malnourished living conditions, who 
predisposed to tuberculosis [77, 1, where 
immunity of the population is undermined by mv infection, the incidence nse 
41,62, 71, 162, 168, 
1.3 Treatment with anti-tuberculosis drug combinations 
Isoniazid (JNH) is a potent anti-tuberculosis with specificity for M 
81, 83]. It is A"""''''!'".!&> In sputum 
In early treatment phase. There is considerable literature concerning the mode 
The LUVJllJ<U form toX:ICll-:V is hepatic injury, which can be severe 
and even fatal Rifampicin is a potent antimycobacterial a broad 
therapy antibacterial spectrum, and it is especially important continuation 
[91]. 
Pyrazinamide is bactericidal against certain populations of mycobacterium [67, 
a polyamine structure. This was ~l"'Y''''-~ 1 thought to 
4 
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suggests the Hl,",''-'''<l.l11''''''' 
activity is bacteriostatic 
Chapter 1 Introduction 
but recent evidence 
inhibition of jO<,IY"V., ... 
139]. 
5 
metabolic labelling 
nneCllve treatment requires to five given concurrently. drugs 
may be administered as single-drug formulations or in fixed-dose combinations, 
where two or more are fixed nrr.nn'f"T1r .... 
combinations such INH PZA have demonstrated empirically that they 
making it attractive to propose rational strategies for the design of 
potentially combinations, Combination therapy be beneficial in that 
inhibitors disrupting an aspect wall biosynthesis may not necessarily 
lethal tnernseJ!ves but affect the permeability drugs 35]. The 
rifamycins activity of isoniazid [89,154]. TB 
chemotherapy to ;:'1.'1" ... ..,',,1.1, it must not only prevent drug resistance, but also kill all 
organisms to prevent subsequent multiplication and [48,49, 103]. 
In practice, efficacy chemotherapy is reduced by a number of '1"<:11"1'('"-,, These 
include hospitalisation, lack adequate supply and delivery, and diagnostic 
.La""'"'",,,. Effective tuberculosis treatment is successful terms of HI"''''''''''''' 
SClence, successful implementation also on socio-economic 
considerations that relate, to political decisions [11, 1 
In deciding on the therapeutic regimen, correct amounts each drug 
.. 
to be determined and individualised [7]. 
While serves an fixed-dose combination may 
treatment difficulties 
5 
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Chapter 1 Introduction 6 
can be attributed to a number of nH",'nr" including non-
compliance [50, 78]. in drug dependence require a detailed addiction 
history[ll, 90, 1 164, 173]. Mycobacterium develop as a result 
of to than the minimum inhibitory concentration (MIC) over 
a slIstained period [47,64, 
DOTS has effective; however, there is a shortage of suitably trained 
personnel to ensure that the necessary procedures are followed, DOTS has been 
less successful [80]. 
treatment tuberculosis, but instead' it does not optimise 
represents a standardised treatment that covers a number of variables [167]. 
Public health authorities have recognised 
status tuberculosis patients, supervised 
to improve the nutritional 
intake, together with 
administration has introduced. However, there is a that food 
alters kinetics, bioavailability compromising the VA .......... "" of 
treatment by sub-therapeutic levels, ."' .......... ,1"> to Prolonged 
treatment ref:l~lmlens may undermine morale, resulting in non-compliance failure 
to achieve effective eradication organism 167]. 
Where mv lflIe:Ctl(m and tuuen.;'Ut{,ISIS infection are common 165], 
poor quality drugs or counterfeit are a 
outcome of treatment is to anticipated 
6 
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1.4 ·Fixed-Dose Combinations (FDCs) 
The WHO togE~tner the International Union l "5 ..... ',;,. Tuberculosis and Lung 
Disease (IUALTD) have advocated replacement ofsingle,..drug preparations by 
in treatment of tuberculosis [1-5, 105, 109, 113]. 
justification recommending that single in primary 
treatment of tuberculosis includes the following: 
• obviate monotherapy, reducing emergence drug-resistant tuberculosis. 
• simplifY treatment, reduce nrl"C!f't"tnftfu'l error increase compliance. 
• FDCs simplifY stock management, procurement and distribution. 
• reduce the of rifampicin for treatment of conditions than 
tuberculosis. 
Emergence drug resistance high-burden areas of the . . IS a major to 
the success of control. resistance in most tuberculosis patients is 
predominantly the result multiple interruptions in [56]. With single 
patients are to interrupt their treatment with some and not with 
others, ...... ""''>i',.., a risk selection of of supplies to 
some drugs being continued without others - another cause of mono therapy. 
As ...,,,Lin,,,l...,,", and treatment failure it is imperative there 
be sound policies and procedures in place managing existing efficiently 
5, 70, 1 
FDCs of good quality should help prevent drug resistance when given as 
observed treatment as part of the 
of rifampicin is essential [11 
evaluation, this 
strategy. Ensuring adequate bioavailability 
are included the If other drugs in 
pro,spe:ClS of 1"1""'''"1''10 a good product. 
Bioavailability data is essential for this purpose [110]. 
7 
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Simplifying treatment 
to swallow fewer pills day would make treatment (Table I). 
FDCs the selection of drugs and reduce Hli .... ""''''''., in calculation of 
dose [178]. 
Table 1. Tablets the intensive treatment phase by a patient 
Single-drug tablets 
Rifampicin 150mg 
Isoniazid (IOO)mg 
Pyrazinamide 400mg 
Ethambutol 400mg (lOO)mg 
Number 
of 
tablets 
tablets 
3 Rifampicin, Isoniazid, 
1 (3) Pyrazinamide, Ethambutol 
3 (150mg+ 75mg+400mg 
9 6) 
Number 
of tablets 
3 
3 
* Figures parenthesis 
number of tablets ' 
to alternative dose formulations and the related 
tablets simplify management drug supply. With single out-of-stock 
situations occur three reasons: no stock, delays in receipt of orders, and 
exp!ry reached without replacement stock being available. With there 
are fewer drugs to consider, ...... n .... 'E,> it easier to calculate needs. 
are drug and distribute, IS 
on Adverse are not more commonly reported for FDC tablets than 
single-drug combinations [179, 180]. 
8 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
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Besides tuberculosis, several common infectious diseases can treated 
successfully with rifampicin. Theft and illegal sale of this drug are not uncommon. 
tablets are much less attractive sale on black-market [177]. FDC 
formulations may tablets, capsules or paediatric suspensions, and are 
manufactured in some countries local use export. 
1.5 Quality of tablets 
It is essential that only tablets of good quality should be [124]. 
in dissolution testing not assure acceptable 
bioavailability of the constituent drugs [69]. a series studies, some had 
acceptable rifampicin bioavailability others did not [23, 59, 69, 109, . 
1 149, 181, 182]. The quality any drug depends critically on 
manufacturing (GMP) [17, 98], which quantities by the 
are not necessarily acquired. Furthermore the physical characteristics 
crystalline structure rifampicin contribute to effective concentration 
drug blood. The materials the manufacturing process can also 
negatively affect bioavailability 88]. 
The bioavailability rifampicin is particularly at if manufacturing 
procedures are not followed, or poor raw materials are used. 
bioavailability leads to unsatisfactory outcomes and may predispose to drug 
Good quality with demonstrated bioavailability of rifampicin and 
other are a prerequisite " ... ..,..,"'"" ....... treatment outcomes with 
regimens [11 140]. 
9 
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Against this background, WHO and IUATLD a joint statement in 1994 
that only FDC tablets of good quality and proven bioavailability of 
rifampicin should be used the treatment of tuberculosis [1 
Pre-qualification of manufacturers is widely accepted as necessary, requiring clear 
specifications, quality product testing adequate monitoring. a pre-
qualification scheme anti-tuberculosis drug manufacturers has been established 
HHliJL"'JlU"'JU~"'''', procurement would be to exclusively 
pre-qualified manufacturers to assure quality. 
Bioavailability of rifampicin should always be demonstrated 
approval and added oen,em would achieved is also 
registration 
for the 
other anti-tuberculosis drugs confined in the using a simplified protocol. 
No correlates of bioavailability are known that do not involve human subjects 
kinetics. the assessment of absorption uptake 
can only be done through clinical studies. Although dissolution testing is m 
evaluating lot-to-10t consistency, it cannot replace bioavailability studies. 
Regulatory approval ofFDC Tablets 
The process is vitally to ensure only of good 
quality are purchased and Not only should the product be of good quality, 
but it should to GMP quality control [17]. WHO and partners are 
working to strengthen registration FDC [84-87, 122]. measures 
include of a laboratory for quality assurance of tablets 
[11 121]. It is increasingly that bioavailability should 
performed all components of the tablet. 
10 
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WHO certificate quality of pharmaceutical product(s) should attached 
specifications should be presented and to imported products. The u~\',~;);)al 
sto~age practices aut .• "" ........... to. ...,O .... ·iULlVUiJ are weak enforcement poor, 
potential for counterfeit and substandard drugs is real. 
1. 7 The market for FDC tablets 
Since Acocella presented his work in Dubrovnik [1 177] FDCs are 
used for treatment of TB. WHO survey of the market 
1998 estimated that approximately of countries used FDCs [106, 107]. 
According to a WHO an estimated of TB cases worldwide 
were with rifampicin-containing tablets. However, most patients 
rp,..~nT" the two-drug combination. 
drug with 75% of cases still 
task to replace single tablets with 
cases are 
treated with single 
in the treatment ofTB. 
three- or four-
It is a major 
1.8 Currents concerns with FDCs and the need for bioavailability and 
bioequivalence t .. ,nlnO' 
has repeatedly emphasized that, to confront the tuberculosis 
aU elements of tuberculosis control 
function optimally An essential component of DOTS is to 
a reliable of good quality Using bioavailability 
leads to poor treatment outcomes and resistance. benefits of improved 
treatment, reduced logistical cost the prevention of MDR-TB further justify 
change to 
11 
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The to establish adequate bioavailability of rifampicin in has 
been recognised. Concern has been expressed about apparent inadequate 
bioavailability of rifampicin some preparations 14-16, 109]. 
Consequently, international regulatory authorities recommend that the 
bioavailability of formulations compared with of ...... "· .... ""r"'Tl 
emcac:y Only those have to bioequivalent should be onto 
t'n"','!rP't [7, 
Whilst over the years focus been on bioavailability of 
within FDCs it is that other anti-tuberculosis drugs 
PZA ETB within FDC as of quality 
assurance procedures. and standardised methods should test quality 
of all drugs that constitute the for regulatory approval and for ongoing 
quality assurance procedures [129]. 
Minimum time-point ..,"'.1""''''' ........ protocol for conducting bioequivalence studies of 
rifampicin using limited sampling time points, showed limited 
[113,114]. 
of precision 
The relative to an existing time protocol 
aimed at reducing the number of sampling points, not just rifampicin, 
to efficient to evaluate formulations currently use in tuberculosis 
programmes as well as those needing approval by the regulator 109]. 
to effective policy, it is essential that low cost quality assurance and 
control procedures form part of standard operating OfC)CeOm 
m medical and terms as it would 
delivery as well as the correct quantity anti-tuberculosis 
12 
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1.9 Factors contributing to the need for minimum time-point quality 
. assurance procedures 
(i) At nr~'''t>l"t it is for pharmaceutical industries to manufacture 
used an extended point protocol, but for industries 
cost becomes a factor. 
(ii) This addresses need to rlt>tt>rtYU"t> the mUl1mum number of 
points for assurance procedures in investigation 
bioavailability, using validated methods according to accepted 
standardized protocols. 
13 
validated bioavailability and bioequivalence protocol that uses minimum time 
would reduce development time and cost, simplifY regulatory requirements, 
achieve standardization, and ensure bioavailability of rifampicin and other anti-
tuberculosis components. To demonstrate consistency in quality, 
principal parameters interest should peak serum (Cmax) and area 
under curve (AUC). 
system should simple, low in cost, and rapid to ensure that pre-qualification 
criteria do not act as a deterrent to manufacturers producing anti-TB Whilst 
support a strict quality assurance on 
containing if other anti-tuberculosis drugs within gIven can be 
determined in a simplified way, this will certainly give added confidence to 
the formulation. 
With the monitoring FDCs the place by independent laboratories, 
bioavailability and bioequivalence would meet required standards on a 
continual [7, 9, 11 17, 123, 159]. A simplified minimum time-point 
protocol would facilitate such a policy. 
13 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
1 Introduction 14 
Objective and Aims 
Objective 
To 'TlU,,,""Tl a number ofscreerlln~Hlme protocols anti-tuberculosis H.tlo.'~U-''''V'''''' 
drug UJUJ(J.U'VU,," to the minimum number of time 
required to bioavailability bioequivalence rA"'>TH1A to an .... ru";nuJ'''''' 15 
time point protocol. 
Aims 
0) conrlprure the bioavailability 13 fixed-dose formulations an 
protocol, approved by the national ..... E, •• u ...... v. authority, to 
of known reference formulations. The following parameters would be 
compared, using concentration-time curves: Cmax, half-life, 
Oi) use the information obtained to assess which of the 
(iii) 
(iv) 
formulations show bioequivalence to r",+;",rc'",.,.", combinations. 
To ... ;:)LeU/H,,,l the llllllUHunl number of time !JUl,'U;:). in a protocol cOIlt3.llrurlg 
time points than conventional and to connoare the bioavailability and 
bioequivalence data obtained with that duration protocols. 
do COnrlpalrawvre analysis on ...... Uj ......... AUCT 
".t"'1"rnn,,,, the minimum number of time IJUlJ'U;:). 
14 
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(v) To conduct subgroup analysis by investigating the number of fixed-dose 
drug formulations as an inclusive data set, for comparison with a number 
of demographic variables. 
(vi) To conduct subject reduction analysis to determine the minimum number 
of subjects necessary for bioavailability and bioequivalence testing of fixed-
dose drug formulations. 
15 
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Action Plan 1 
Objective: accomplish aim (i) 
. Collection specimens 
. (patients or Healthy Volunteers) 
f 
Assay of specimens/samples . 
I 
Bioavailability 
Students t-Test 
Wilcoxon rank test 
(p< 0.05) 
of 
. 16 
and Aims 
Products 
Reference (individual) 
Test (fixed-dose combination) 
Analytical Laboratory 
l.C1U,.,,,,U',,,,, Analysis 
Confidence 
(80-125%) 
16 
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Action Plan 2 
Objective: To accomplish aim (iii) Objective and 
3 Clinical Trials Products 
Information/Data Obtained -
Action Plan 1 
Extended Time Protocol 
methodology (phase 1) 
Capture in 
Pharmacokinetics 
WinNonHn 
Bioavailability 
Statistical Analysis 
Students t-Test 
Wilcoxon signed rank test 
0.05) 
17 
(individual) 
(fixed-dose combination) 
Chapter 4 
11 - Phase 2 
0, O. 1.0, 1 2, 
.0,4.0,6.0,8.0 (hours) 
GTime • Phase 3 
0, 1 2.0, 
Analysis 
Hauschke Analysis 
Confidence Interval 
(80-125%) 
17 
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Action Plan 3 
Objective: To accomplish aim (iv) and (v) of Objective and Aims 
Volunteers 
Patients 
formulation 
combination formulation 
Bioa',ailabiiitj' I-I~ Conclusion 
Products 
poTpolrpo"I''''' (individual) 
(fixed-dose combination) 
+ ..... f ......... Variances 
Waldens test -
Four Drug 
Dose Combination 
Pharmacokinetic Parameters 
24, 
Bioequivalence 
~--------------------------------~ 
18 
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Chapter 2 Methodology 
Chapter 2 
Methodology 
19 
The study computerised apt)UCiattcm software j.Ja .. ,n.a.j","''' as a tool 
parameters in a comparative way, that allowed for 
determination of optimum minimum protocol. The 
obtained allowed for the investigation of bioavailability and bioequivalence 
fixed-dose drug ,",Vluu"ua"lVl." and how this cornpakred to the necessary 
standards, 
Studies Investigated 
Table 2 indicates the .. ptlF'''P" and test products, with the source, that 
wer:e utilised in each studies, the that constituted 
drug combinations and >AUU''''''''' of in each, Appendix 
the that was used the first period of of 
respective studies The reverse sequence was used for the second period 
the washout period. exception was Study 1 which was not a "la,);:)lloJa! 
double cross over design, but instead extended across three periods. 
Table ated 
Test Test Reference Dose 
Product Product Product (mg) 
Dose 
(m ) 
Study 1 Isoniazid 4xlOO 
Rifacap (Quatromed) 4x150 
Healthy Volunteers (16) 
etit 
19 
Total 
Dose 
400 
600 
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Test Test Reference Total 
Product Product Product Product Dose 
Dose Dose (mg) 
(m ) m 
Study 1 INH 2x150 (Lennon) 3xlOO 300 
Rifinah 300 RIF 2x300 ( Quatromed) 4x150 600 
July 1996 
Healthy (16) 
Study 2 5x60 3xlOO 300 
RIF Sx120 (Ciba) 4xlS0 600 
December PZA 5x300 3xSOO 1500 
Healthy (24) ETH 5x225 Mycrol (Rolab) 2x400 
Lederle 3.25xlOO 1 
Study 3 INH lOx30 3xlOO 300 
Rifcin 10x60 4xlSO 600 
February 1 lOx 1 50 3x500 1500 
Ciba 
Study 4 5x60 Isoniazid 3xlOO 300 
Rifcin Co 5x120 Rimactane (Ciba) 600 
April 1997 5x300 1500 
TB Patients (22) 
• Ciba 
Study 5 10X60 Isoniazid 6xl00 600 
RifcinPed RIF 10x60 Rimactane (Ciba) 4x150 600 
April 1 
TB Patients (19) 
Ciba 
20 
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Test Test 
Product Product 
Dose 
(m ) 
Study 6 RIF Ix600 
Rifadin 
1997 
Healthy Volunteers 
HMR 
Study 7 INH 5x60 
Rifafour 5x120 
October 1997 5x300 
Volunteers 5x200 
Study 8 INH 5x50 
WHO 
April 1998 5x120 
Volunteers 5x300 
Study 9 lOx30 
""",UHau Ped 
Volunteers (24) 
HMR 
21 
Product 
(Ciba) 
Mycrol (Rolab) 
Medical) 
Rimactane 
Rozide (Rolab) 
(HMR) 
Rifadin (HMR) 
Product 
Dose 
lx600 
3x100 
lx600 
3x500 
2x400 
2xlOO 
2x100 
Ix50 
4x150 
3x500 
3xlOO 
Ix600 
21 
Total 
Dose 
600 
600 
1500 
1000 
600 
1 
300 
600 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Chapter 2 Methodology 22 
Test Test Reference Reference Total 
Product Product Product Product Dose 
Dose Dose (mg) 
m) 
Study 10 INH lOx30 Norstan-Isoniazid 3xlOO 300 
Rifater (HMR) lx600 600 
August 1998 lOx150 (HMR) 3x500 1500 
Healthy Volunteers (21) Rozide (Rolab) 
Study 11 Norstan-Isoniazid 6xlOO 600 
Rifinah1501150 RIF 4x150 (HMR) lx600 600 
November 1998 i Rifadin (HMR) 
Healthy Volunteers (22) 
HMR 
Study 12 INH 4x75 N orstan-Isoniazid 00 300 
Rifinahl (HMR) Ix600 600 
1998 (HMR) 
• Healthy Volunteers 
INH 4x75 Norstan-Isoniazid 3xlOO 300 
RIF 4x150 (HMR) lx600 600 
January 4x400 Rifadin (HMR) 4x400 1600 
Healthy (24) (HMR) 2x400 
HMR Rolab-Ethambutol 1100 
(Rolab) 
Rolab-Ethambutol 
22 
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2.2 Methodology 
clinical trials conducted in the Department of Pharmacology, University 
Cape Town since 1996 which followed internationally accepted standardised 
principles for bioavailability and bioequivalence [16, 17, 144, 145] and 
monitoring 28] were investigated or validated as part of ongoing rpl;!,"'$Irl'n 
95-97, 101, 157, Ethical approval from the Ethics Committee of 
. University Cape Town and the Control Council had 
obtained prior to the start of each study. 
studies included 2, 3 and 4 fixed-dose drug combinations consisting of 
rifampicin, isoniazid, pyrazinamide and ethambutol, respectively, given as a single 
reference principal and as fixed combination active principal one week apart to the 
same subjects in a randomised open within-subject cross over design [102, 1 
151]. 10 studies were investigated in healthy and 3 in all of 
whom had fulfilled the inclusion, and none of the exclusion and had 
written consent (Appendix I). 
It is important to have an understanding of the exact function and purpose 
individual constituents, the formulation of fixed-dose anti-tuberculosis 
conabillatlions [76]. Table 3 modified Davidson Quoc Le's article, 
anti-tuberculosis drugs into different classes and an 61]. 
23 
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Table 3. and Gradin anti-tuberculosis s 
1 2 3 
Description Drugs with Drugs early with sterilising . 
of resistance revention activit 
Drug and INH 
In RIF 
decreased INH 
order of 
effectiveness 
Comment These agents These induce having the 
combined can rapid decrease the ability to kill all 
prevent the number of tubercle the 
emergence bacilli in of 
resistant mutants to at of experimental 
the companion drug. treatment to (probably humans) 
negative cultures the relapse 
thus risk of rate to a minimum 
transmission. within a short eriod. ! 
2.3 'Analytical Methodology 
:sm~CH1nen collection venous blood was obtained at the sannpltn,g times 
were required clinical study and the high performance liquid 
(HPLC) of Zent Smith [29] was the 
laboratory in the Department of Pharmacology, University of 
Town to analyse rifampicin, isoniazid and Q.LLUQ,J,.UU\;>. For ethambutol the 
modified method of Lee Wang [22, 104, 112, 1 was used. Figure 1 
aelJIC1CS the chemical structure of the anti-tuberculosis investigated. ...,,"'u ..... "' .... 
24 
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pyrazinamide are similar chemical structure and Size, making them 
attractive synergistic drugs in the design combinations. Ethambutol has a 
more polyamine chemical while rifampicin has a larger ULV."'.., ....... 
structure to the other investigated and is potentially vulnerable 10 
crystalline form due to polymorphism [88]. 
H3 
Rifampicin and Desacetyl Rifampicin 
Rtmoval (*) = Rifampicin 
H 
H~N 
Ethambutol 
[[~ O~·X """~N-NH H :2 
Pyrazinamide 
1. Chemical structure of anti-tuberculosis drugs investigated 
2.4 Statistical and Pharmacokinetic Analysis Methodology 
Upon (·{UnT ..... r of the and assay methodology, using analysis, 
data obtained for the 13 respective clinical was captured or validated 
investigator using a computer-based widows program WinNonlin Standard J...:.U1U'-'U 
Version 1 (WinNonlin 1984-1997, Scientific Consulting, Inc), developed to 
evaluate using nonlinear modelling. 
25 
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model uses one or more partial derivatives to determine parameters 
compartments that have or non-linear kinetics 61]. This makes the 
application suitable for pharmacokinetic pharmacodynamic modelling and 
noncompartmental analysis 152]. 
Taking consideration that a single dose was administered at zero, 
noncompartmental or model independent analysis described the concentration-time 
curve by estimating noncompartmental parameters such as: area under the curve 
(ALJC), time at maximum concentration is reached (Tmax), the 
maxImum concentration achieved (Cmax) Lambda z, the rate constant 
u,,"u .... 'u .... 'u with the terminal elimination 
The was m spreadsheet format as was required for WinNonlin 
application (Appendix 2) 
information: subject 
the various studies and consisted of the following 
"'-'.0'''' ....... ''' time when blood spe:Ctnlen was 
code combination, code the period when the combination 
was taken and concentration for the respective within fixed drug 
cOhJbination as measured from the venous blood. 
use of schedule information as well as drug concentration 
levels, concentration-time curve for each the series of drugs a 
particular study were obtained (Appendix 3) WinNonlin and analysed. The 
derived this analysis, together the resnec::;n\re 
allowed the descriptive pharmacokinetic parameters, being, 
terminal llUlJ'-UJ.,",_ area under time curve and area to infinity 
the drugs to be generated. 
uses linear trapezoidal calculation up to 
Cmax, 
the linearllog 
logarithmic 
and the 
logarithmic trapezoidal rule is after has been achieved. 
parameters obtained were used to evaluate the bioavailability and bioequivalence 
of the FDC. 
26 
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In all the studies, as their own control allowing the use of the 
paired t-test (parametric test) to statistically evaluate the comparison between the 
the test. t-test assumes that the population of follows 
a distribution or normal distribution. Many statistical tests depend on the 
assumption the values sample were obtained a population that 
follows a bell-shaped curve. the normal distribution differences 
cannot assumed, Wilcoxon pairs test 
was also used to confirm results. The non-parametric tests make 
assumptions about the distribution of the data. P-values than in the two 
tailed test were considered to be 
widows-based GraphPad Prism® 
analysis was determined in 
2.01 (GraphPad Software© 
1994,1995,1996 GraphPad Software, Inc). 
For bioequivalence testing of respective formulations analysis was 
conducted according to methods described by Hauschke et al The 
pharmacokinetic variables of principal importance are 
Bioequivalence was declared 90% interval for test IrAi'prAnr.A 
ratio was completely within the range 80-125%, which is the acceptable standard 
set by regulatory authority. Widows-based Microsoft ® SR-2 
f985-1997 Microsoft was by formulating a in 
the application to the parameters as described by 
1986-1 
and other basic statistics were achieved using 
software programme SigmaPlot® 
Jandel Corporation), 
© 
procedure process that was followed to investigate the minimum time 
points required to evaluate a given fixed 
above. data followed 
combination was as described 
order, rifampicin, ."'v.n ..... " .... , pyrazinamide 
27 
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and ethambutol, where one or more of the anti-tuberculosis were present as 
reflected Table 4, to.Q;eth.eI with the ex[)ectea therapeutic concentration 
1 146]. 
TabJe 4. Anti-tuberculosis and recommended therapeutic range 
t'rCIDo:sea 2 hour Usual Dose 
Rifam icin 600-750 
30-450 
P azinamide 20-60 1000-2000 
Ethambutol 2-6 15-25 
Table 5 ren_ects the DrotOCOl schedule with the vALvll~tvU time protocol 
that' is used as policy (phasel), the optimum time points (Phase 2) and 
the desired minimum time points (Phase 3) which were evaluated in this study. 
Table 5. optimum desired time protocol schedule. 
No. Extended Extended Optimum Desired 
Time Time Points Points Time Minimum 
Points (hour) (hour) Points Schedule 
(PZA) (RIP, (hour) (hour) 
Phase 1 Phase 1 Phase 2 Phase 3 
1 0.00 0.00 0.00 0.00 
2 0.25 0.25 0.25 1.00 
3 0.50 0.50 0.50 2.00 
4' . 1.00 1.00 1.00 4.00 
5 1.50 1.50 1.50 6.00 
6 2.00 2.00 2.00 8.00 
7 2.50 2.50 2.50 
8 3.00 3.00 3.00 
9 4.00 4.00 4.00 
10 6.00 6.00 6.00 
11 8.00 8.00 8.00 
12.00 12.00 
13 24.00 24.00 
14 36.00 
15 48.00 
28 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
The time 
work 
chosen 
et al [109] 
2 Methodology 29 
2 time were based on published 
Mc1lIeron et al [113] that concentrated on 
rifampicin in dose combinations where time points up to 12 hours were used 
and 48 when pyrazinamide was included. Taking practical considerations 
into account clinical 8 was as the last 
sampling point in the investigation as the would have already been 
attained. 
accuracy. 
curve 
time points around the anticipated 
the phase 3 time protocol the 
not on ........ ,.u.rt.. 
were to maintain 
was placed on area the 
was implemented for the phase 2 and phase 3 time The process 
protocol, as .... "' ....... ' .... by optimum and the mInImUm schedule, 
from the avT," .... n 
all the 
intervals were 
To determine 
selecting 
de-select, the initial set the relevant points 
protocol, to the WinNonlin and Hauschke analysis for 
in the 13 ';)~U\"lv" and to evaluate "' .. ""....... results 
compared to that of the "'A."' ..... "' .... time protocoL 
minimum ""JlUIJ'''. of subjects, protocol followed de-
from a sen~Clt:u drug fixed combination study. 
outcome had to achieve similar results and confidence intervals to that the 
extended protocol to be suc;ce:sSDJI and verifY the mlIumum number. 
Sub-group and correlation analysis were investigated for all 13 studies as 
a collective data set. Comparisons the collective data set were derived the 
principal versus the 
combination, influence of sex and that of status. The same 
application and statistical methods were applied as in investigations the 
29 
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optimum minimum points. Where this was not possible based on unpaired 
sets, due to ..... ",:.",1"" not completing both arms a given study, the iVUI.Ull-
Whitney non -parametric test was applied. 
the logarithm of the difference between the 
residual maximum algorithm \.L'U.":'H'.LJ..J 
models were to 
ame:ters [148, 1 
GenStat © 2002 
I-IA""fi.A~~v was used for the as opposed to the standard 
maximum likelihood method. The standard maximum likelihood method estimates 
of variance components tend to be underestimated, v",,",,,, .. ,,.,,, they do not take 
account the loss of tipeJrPI"C! freedom due to the eStlmaltlon effects. 
REML is intended to this problem. 
30 
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Chapter 3 
Extended Time Protocol Results 
3.1 BioavailabiHty and Bioequivalence 
A short outline describing each of the studies investigated is presented. Figures 2 
to 15 and Tables 6 to Table 19 and Table 20 present the results of the studies and 
summarises the bioavailability and bioequivalence analysis with respect to these 
studies. The tables present the data in reference and test formulations of the 
pharmacokinetic parameters Tmax, Cmax, half-life, AUCT and AUCI including 
the mean and standard error of the mean (SEM). The units of measurement for 
each of the parameters are indicated in brackets; Tmax (h), Cmax (mgll), Half-life 
(h), AUC and AUCI (mg.hll). The parametric Students-t-Test and non-
parametric Wilcoxon Signed Rank test were used to determine statistical 
significance between the reference and test formulations. Significance was 
declared where the p - values obtained were less than 0.05 when comparing the 
reference to the test. For bioavailability to be successful, for both the reference 
or test of each of the respective drugs, Cmax should be within the therapeutic 
range as defined in Table 4. 
For bioequivalence . testing, the parameters of importance, i.e. Cmax, AUC and 
AUCI were summarised with respect to the point estimate, test/ reference ratio, 
the percentage span (the difference between the upper and lower confidence 
interval), and the most important parameter in the assessment, the 90% 
confidence interval of the respective drugs. Where the data falls within the 
confidence interval (80-125%) the data is presented in bold and when not within 
the required parameters, presented as ordinary text. An explanation and 
conclusion of each of the studies are provided to the figures and tables of the 
respective studies in the following order: Cmax, AUC and AUCI. Tmax and half-
31 
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life data are presented as part of the graphics but the general and overall 
conclusion across all studies is that Tmax and half-life were comparable with 
some exceptions in Tmax mainly due to the nature of the formulation relative to 
the reference. 
Study 1 
The objective of the study was to compare the bioavailability, In healthy 
volunteers, of rifampicin and isoniazid in fixed combination formulation tablets 
Rifinah 150 and Rifinah 300, to the bioavailability of the reference single agents, 
rifampicin and isoniazid, currently registered In South Africa for use In 
tuberculosis therapy. Data from this study is summarised in Fig 2 and 3 and 
Table 6 and 7 taking into consideration both components of the respective 
studies. Study 1.1 (Rifinah 150) and Study 1.2 (Rifinah 300) investigated two 
different dosages relative to a reference in a three way cross-over design with 
subjects randomised in period one and period three of the study and receiving the 
reference in period two. For the bioequivalence analysis, two assumptions are 
made: (l) that subjects received the reference drug in period one and the test 
drug in period two (2) for purposes of the analysis the first eight subjects received 
the drug in the order of reference then test and the second eight received it in the 
reverse order. 
32 
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1.4 
INH 1.2 
1.0 
7 
6 
5 
4 
3 
2 
Study 1-1 
4 
3 
2 
1 22.5 
0.8,.....-_--, 
1 
0,.....-_--, o ,.....-_--, 20.0 ,.....-_____ ----, 
18 3.0 
RIF 2.0. 16 
1.5 T max 
(h) 
14 
12C max 
(mg/l) 
_ Reference 
2.5 T1I2 
(h) 
2. Bioavailability of study 1.1 
1.1 
i N::;;16 
HV 
Cmax 
AVCI 
Cmax 
AVC 
AVCI 
Median! Point 
Estimate 
100.68 
103.71 
94.10 
Reference 
Ratio 
Isoniazid 
0.94 
0.97 
0.95 
0.99 
1.07 
1.04 
33 
85 
80 
75 
70 
65 
60 AVCT AVCI 
(mg.hIl) 
90% 
Confidence 
Interval 
81.61-112.56 
87.88-116.11 
89.17-120.17 
62.46-144.96 
38.95 
68.17-133 
% 
28.23 
30.99 
82.50 
70.52 
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Both Study 1.1 and Study 1.2 concluded bioavailability based on Cmax, AVCT 
and AVCI, with no significant difference to the reference. Bioequivalence was 
concluded within the confidence interval limits for INH in both study 1. 1 and 
study 1.2 for parameters Cmax, AVCT and AVCI, but not for RIF. The 
product formulation was successful based on the assessment of bioavailability 
data only indicating that both drugs were bioavailable although not bioequivalent. 
1.4 
INH 1.2 
1.0 
7 
6 
5 
4 
3 
2 
Study 1-2 
4 
3 
2 
T 32.5 
30.0 
27.5 
25.0 
22.5 
0.8~_-, 0,--_-, o ,----=--, 20.0 ,---______ ---, 
2.0 
1.5 
RIF 
1.0 
0.5 
0.0 
'Fmax 
(h) 
16 
14 
12 
3.0 r-
,l-
DJ 1.5 
O. 0 '---"""'--'--'----' 
Cmax 
(mg/I) 
rl/~ 
(h) 
_ Reference CJ Test 
Fig 3. Bioavailability results of study 1.2 
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T bl 7 B' . I It ftd 12 a e . lOeqmva ence resu s 0 s U lY . 
Study 1.2 Median/ Point Test/ 90% % Span 
N=16 Estimate Reference Confidence 
HV Ratio Interval 
Isoniazid (INH) 
Cmax 106.59 0.92 93.11-123.76 30.64 
AUC 102.04 0.96 91.88-114.33 22.45 
AUCI 110.50 0.94 96.12-123.65 27.53 
Rifampicin (RIF) 
Cmax 88.16 1.01 69.31-119.74 50.43 
AUC 94.76 1.06 72.70-133.29 60.59 
AUCI 102.09 1.06 87.90-139.66 51.77 
Study 2 
The first objective of the study was to compare the bioavailability, in healthy, 
volunteers of a Myrin-P fixed combination tablet consisting of rifampicin, isoniazid, 
pyrazinamide and ethambutol as a single dose to that of the reference tablets of 
rifa~picin ( capsule), isoniazid, pyrazinamide and ethambutol tablets as single 
doses. The second objective was to establish whether the Myrin-P fixed 
combination formulation is bioequivalent to equivalent doses of the drugs in the 
reference products. 
The study (Fig 4) demonstrated bioavailability based on Cmax in INH, RIF, PZA 
and ETB with no significant difference when comparing the test product to that of 
the reference with the same drug constituents. AVCT and AVC! showed no 
significant difference in RIF and ETB but did for INH. PZA, in test and 
ref~rence was not significantly different In AVCI but in AVCT. The 
bioequivalence analysis (Table 8) concluded that the parameters Cmax, AVCT and 
AVCI for INH, RIF and PZA were within the required confidence limit including 
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of ETB. Based on AVC and bio-
The product formulation was declared succes:sruJ based on the 
bioavailability and bioequivalence assessment. 
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Study 2 
N=24 
HV 
Cmax 
AUC 
AUCI 
Cmax 
AUC 
AUCI 
AUC 
3 
Median/ Point 
1 
1 
95.00 
15 
106.03 
Test! 
Ratio 
Isoniazid 
1.02 
1.19 
1.17 
1.08 
1.10 
1. 
0.98 
1 
1 
Ethambutol 
1.08 
1.17 
1.18 
37 
Results 
90% 
Confidence 
Interval 
83.17-105.29 
108.76-126.30 
106.31-120.07 
95.30-114.10 
100.15-116.49 
99.77-115.82 
91.10-100.14 
103.11-108.59 
93.27-97.87 
84.27-114.70 
90.12-125.05 
87.23-136.29 
% Span 
1 
18.79 
16.34 
16.05 
9.04 
30.42 
34.94 
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Study 3 
The objective of the study was to compare the bioavailability, in patients, of 
rifampicin, isoniazid and pyrazinamide for the fixed drug combination of Rifcin 
PedZ tablets to the bioavailability of the reference single agent products, 
rifampicin ( capsules), isoniazid (tablets) and pyrazinamide (tablets) currently 
registered in South Africa for the treatment of tuberculosis. 
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The study concluded (Fig 5) that adequate bioavailability of all three drugs was 
achieved and comparable to the reference. Bioavailability was achieved for Cmax 
that was not significantly different for RIF and PZA but that of lNH was 
significantly different. AUCT and AUCI showed partial significantly different 
resl,dts for lNH. RIF showed a significant difference for AUCT and AUCI and 
PZA showed no significant difference for the same parameters with respect to 
bioavailability. 
T bi 9 B' , 1 a e . loeqmva ence resu ts 0 f d 3 stu ly 
Study 3 Median! Point Test! 90% % Span 
N=16 Estimate Reference Confidence 
Patients Ratio Interval 
Isoniazid (INH) 
Cmax 126.06 l.35 101.62-148.53 46.91 
AUC 12l.95 1.53 100.87-144.48 43.61 
AUCI 122.81 1.54 104.79-122.81 44.67 
Rifampicin (RIF) 
Cmax 111.32 1.20 89.10-143.41 54.31 
AUC 127.08 1.32 109.72-154.01 44.29 
AUCI 125.88 1.32 109.34-155.36 46.02 
Pyrazinamide (PZA) 
Cmax 108.22 1.07 96.97-118.82 21.85 
AUC 102.01 1.00 91.48-108.08 16.60 
AUCI 101.01 0.99 89.12-106.12 17.01 
Bioequivalence as presented by Table 9 was shown completely for PZA and only 
for AUCI for INH. RIP did not fall within the desired confidence interval as 
required for aU parameters of Cmax, AUCT and AUCI. The product was 
successful based on bioavailability falling within limits with respect to Cmax 
although the bioequivalence was unsuccessful. 
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Study 4 
The study objective was to COIIlOar in patients, the bioavailability of rifampicin, 
isoniazid and combination of Rifcin Co tablets to 
the bioavailability achieved by r"'tj"'r""n ... '" single agents, rifampicin (capsules), 
isoniazid (tablets) and pyrazularrnae (tablets) currently registered in South Africa 
for the treatment of 
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The study, as indicated by Fig 6 concluded bioavailability for Cmax with respect 
to all three drugs that was not significantly different to that of the reference. 
AUCT and AUCI for both INH and PZA showed no significant difference, but 
RIF showed significant difference for AUCT and a partial significant difference for 
AUCI. 
T hI 10 B' , 1 a e . 10eqmva ence resu ts 0 f d 4 stu Ly 
Study 4 Median! Point Test! 90% % Span 
N=22 Estimate Reference Confidence 
Patients Ratio Interval 
Isoniazid (INH) 
Cmax 95.62 1.05 80.43-113.37 32.94 
AUC 88.14 0.97 79.73-111.05 31.32 
AUCI 89.28 0.98 80.78-110.67 29.89 
Rifampicin (RIF) 
Cmax 88.95 0.95 70.31-111.35 41.04 
AUC 84.30 0.90 67.03-108.69 41.66 
AUCI 84.48 0.89 67.21-108.91 41.70 
Pyrazinamide (PZA) 
Cmax 104.45 1.04 96.09-111.16 15.07 
AUC 98.89 0.99 95.80-102.46 6.66 
AUCI 99.72 l.00 95.82-103.22 7.40 
Bioequivalence as presented by Table 10 was within the 90% confidence interval 
for all parameters for INH and PZA but not for RIF. Adequate bioavailability is 
shown for the formulation with respect to Cmax, but based on the bio-
inequivalence ofRIF renders the product formulation unsuccessfuL 
41 
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Study 5 
The objective was to compare bioavailability in patients 
rifampicin and ... 'Vj'u ..... " ..... , in fixed drug combination Rifcin Ped tablets, to 
bioavailability achieved by the single reference 
isoniazid (tablets), currently registered m 
tuberculosis. 
Study 5 
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Africa for treatment of 
AUCI 
The study as summarised 7 showed that bioavailability both INH and 
RIF for all the pharmacokinetic parameters investigated was successfully achieved 
both test and ,..",1';",,..,,,,,,,,,,, formulations. 
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AUC 
Chapter 3 bX1Cen(Jea 
Median/ Point 
Estimate 
98.35 
104.12 
105.07 
90.69 
94.37 
94.22 
5 
Ratio 
Isoniazid 
1.09 
1. 
1.15 
0.97 
Protocol Results 
90% 
Confidence 
Interval 
87.46-114.80 
95.16-118.54 
96.24-120.51 
77.32-109.09 
84.42-106.20 
84.53-108.62 
% 
31 
21 
43 
analysis as nresenlea in Table 11 concluded that AVCT 
was within the desired confidence for both INH and 
Bioequivalence for Cmax was succeSSIUl INH, but not for was 
the confidence interval. The lU .... ' '' • .,'Vll was successfully avll."'''''',", 
on bioavailability and 
6 
of the study was to compare 
''''1"~.''''r'' of rifampicin for Rifadin tablet to 
drug nalnpllcm Rimactane (tablet) as reference and 
,,;:)Ul.UH')H whether two formulations were 
,",V",",,,,,,,,,,,,''' bioavailability as 
and AVC!. 
bioavailability in healthy 
rifampicin in the 
In 
second objective was to 
a single dose. 
8 for RlF for all 
of Crnax, AVC and AVCI compared to that of the reference 
formulation investigated. Bioequivalence as nresen.tea In 
43 
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Cmax, AUC AUCr. product formulation was successful based on 
bioavailability and bioequivalence. 
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Study 7 
objective of study was to compare the bioavailability in healthy volunteers 
Rifafour fixed combination as a single consisting of rifampicin, 
, pyrazinamide ethambutol to of the reference of 
rifampicin, ... 'v.u"''''' ..... , pyrazinamide and ethambutol tablets in single doses. The 
second objective was to establish whether the fixed combination formulation, 
Rifafour, is bioequivalent to doses of the same reference products. 
The study found, as demonstrated in 9, that bioavailability was ,.pnl ... ".~n 
the parameters Cmax, AUCI for aU four drugs, in the fixed-dose drug 
combination with no significant difference to the respective 
Bioequivalence as presented by Table 13 complied within the desired 90% 
confidence interval for all parameters of Cmax, AUCT and AUCI for all the drugs. 
The product formulation was 
bioequivalence data. 
successful based on bioavailability and 
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Study 7 
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Table 13. Bi 
Study 7 Test! 900/0 0/0 Span 
N=23 Estimate Reference Confidence 
HV Interval 
Isoniazid 
Cmax 100. 1.06 89.80-1 
AUC 95.47 1.04 89.16-107.76 18.61 
92.54 1.01 87.09-105.77 18.68 
101 l. 92.87-119.06 26. 
105.98 1.13 98.02-115.01 16.99 
AUCI 107.77 1.11 
P razinamide 
104.24 1.04 100.32-110.97 10.65 
1.01 95.68-103.24 7.57 
AUCI 99.41 1.02 95.84-105.61 9.77 
Ethambutol 
1.06 89.85-114.06 24.20 
AUC 100.44 1.09 90.90-113.45 
AUCI 98.71 1.10 88.12-113.35 
Study 8 
The objective study was to do a blinded study to compare the bioavailability 
of and metabolite desacetyl rifampicin, a single fixed-dose 
combination tablet to a bioavailability of a fixed-dose 
combination tablet(WHO), consisting of rifampicin, isoniazid, pyrazinamide was 
compared to that the reference as a single dose in healthy 
volunteers. second objective was to establish whether fixed combination 
47 
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Table 14. 
N=19 
HV 
8 
AUC 
AUCI 
Cmax 
AUC 
Chapter 3 tXltenllea Time Protocol Results 
uivalence results of stud 8 
Estimate 
100.48 
101.11 
100.23 
100.88 
Test! 
Reference 
Ratio 
1.06 
1.04 
1.12 
1.11 
90% 
Confidence 
Interval 
89.21-115.19 
92.20-112.26 
10.72 
93.09-122.47 
87.02-120.87 
1.06 83.56-112.79 
% Span 
25.98 
20.07 
17.87 
33 
study assayed only RIP and DRIP and as indicated Fig 10, 
49 
demonstrated bioavailability within the required range RIP and metabolite 
DRIP, parameters Cmax, and that was not significantly 
Bioequivalence usmg Hauschke was as 
presentea by Table 14 fell the confidence interval as required for 
~u"""a, AVCT AVCI. product formulation was declared successful 
on bioavailability and bioequivalence data. 
Study 9 
objective of study was to compare the bioavailability in healthy 
Powder as a single 
COI1lSlstmg of ...., .... , .... ,1"1 and l.:lVIUla.<.lU, to that of the rifampicin 
and isoniazid as single dose tablets. second objective was to establish whether 
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the formulation Rifinah Combination Paediatric Powder IS bioequivalent to 
equivalent of the 
conclusion of 
significantly 
In reference 
study (Fig 11) demonstrated bioavailability 
relative to the respective f'l'>t'I"f'l'>ln .... 1'> 
and respectively. BioavaiIability ame~ters AVCT and AVCI 
was 
INH 
showed no significant but for were significantly 
when VVU,A..,"" test to f'l'>t'F'f'l'>n .... 1'> formulations. 
Bioequivalence analysis as presented by Table 15 was satisfactory for and 
AVCI INH, but not for for the same drug. showed bio-inequivalence 
for AVCT , AVCI and Cmax. product formulation was bioavailable within 
required limits but test product was declared unsuccessful to the 
bio~quivalence 'ameters not falling the C0l1IlClem:::e 
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Table 15. Bioe uivalence results 9 
Study 9 Medianl Point Test! 90% % Span 
Estimate Reference Confidence 
BV Ratio Interval 
Isoniazid 
Cmax 78.93 0.83 89-88.58 1 
94.29 1 82.20-106.66 24.46 
AUCI 1.01 81.95-108.88 26.92 
Study 10 
The objective the study was to compare the bioavailability healthy 
volunteers of Rifater Combination Paediatric Powder sachets as fixed-dose 
combination, consisting of rifampicin, isoniazid and pyrazinamide to that the 
rpt."'rplr1(,p individual drugs, rifampicin, .i>VU1ULol .... and pyrazinamide as single 
tablets. second objective was to establish whether formulation Rifater 
Combination Paediatric sacllets is bioequivalent to equivalent the 
drugs the reference products. 
51 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
1.0 
0.5 
0.0 
Chapter 3 Extended 
6 
4 
2 
o 
15 
10 
Study 10 
4.5 
3.0 
11 
0.0 
3.0 T 
20 
87.5 
75.0 
1.5 62.5 
0.0 
1.5~-~ 
PZA 1.0 ~ 
0.5 
0.0 
Tmax 
5 
o 0.0 
40 8 
30 6 
20 4 
2 
o 0 
(h) (mgVI) (h) 
-
12. Bioavailability results 10 
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study concluded as indicated 
respectively was bioavailable 
showed that Cmax for 
also not significantly 
52 
and 
to 
respective reference was bioavailable, but significantly 
to that of the ,..",t;"",..""n,..", AVCT and AVCI for were not 
different, in the test these 
were significantly 
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Table 16. 
Study 10 Median! Point Test! 90% % Span 
Estimate Reference Confidence 
BY Ratio Interval 
Isoniazid 
Cmax 79.77 0.81 73.37-83.75 10.38 
AVC 93.01 86.64-97.70 11.05 
AVCI 91.16 0.92 85.64-96.33 10.69 
Cmax 88.04 1.01 81.38-104.10 22.72 
AVC 97.21 1.06 87.70-1 
AVCI 96.48 1.07 88.59-1 23.84 
P razinamide 
Cmax 104.41 1.08 1 
AVC 110.96 1.11 106.86-1 8.18 
AVCI 111.08 1.11 107.51-114.80 7.29 
The bioequivalence summarised in Table 16 were satllstaictoJry 
parameters Cmax, AUCT and AUCI for and PZAand INH only 
and complied. product formulation was successful on 
bioequivalence. 
Study 11 
The ..... 1'\'''' .... 1', of the bioavailability healthy volunteers 
of Rifinah 1501150 .fixed-dose combination tablets, consisting of rifampicin and 
I.:lVlUa, .... ...., as a to as a 
The second objective was to establish the 
combination formulation Rifinah 15011 fixed combination tablets is bioequivalent 
to doses drugs in the 'l'p"tS:''I'pn products. 
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13. Bioavailability results study 11 
54 
study concluded (Fig 1 that INH and RlF were bioavailable in rpt,p.rplr'1rl'> 
test based on parameters AUCT AUCI. comparison 
test to rpt'::'rpn products respectively showed no-significant difference. 
Bioequivalence analysis preseUleu in Table 17 was adequately "rn .... ".·., both 
INH and for the analysis parameters Cmax, AUCT and £1'U ..... d .. The product 
formulation was successful based on both bioavailability and 
bioequivalence 
54 
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Table 17. Bioe uivalence results of stud 11 
Study 11 
N=22 
HV 
Cmax 
AUC 
AUCI 
Cmax 
AUC 
AUCI 
Study 12 
The objective 
Rifinah 
as a single 
Median! Point 90% % Span 
Confidence 
Interval 
Isoniazid 
98.79 0.93 85.18-11 26.44 
102.07 1 93.95-1 20.55 
1 1 93.54-1 22.36 
Rifam 
95.61 0.97 86.21-106.46 20.25 
97.96 1.02 90.36-109.96 19.60 
97.33 1.03 89.11-109.10 19.99 
study was to the bioavailability in healthy volunteers 
combination tablets consisting rifampicin and isoniazid 
to the reference ~"""J''''~''' rifampicin as a 
dose, The seCicma 
formulation 
objective was to establish whether the 
150175 fixed combination tablets is 
dose combination 
to equivalent 
doses of the 
The study 
respect to 
in the reference products. 
as mdIca'ted 
with no significant ,,. .. ' .. "',,."''''', 
14 that 
difference 
was bioavailable with 
companng test 
to reference product. RIP was bioavailable with respect to Cmax, but 
companng test to the reference, was a statistically significant difference. 
For AUCI showed no 
statistical SH!IUIl(:am: different rI:>H1JT1UI:> to the reti~rellce 
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Bioequivalence as nY"""::'T1,t",rI by 18 was satisfactory for 
and AVCI for but not for Cmax which 
inequivalence. formulation was declared 
bioavailability and data. 
Study 12 
1.0 6.0 3.0 
INH 4.5 20 
0.5 3.0 1.5 15 
1.5 
no no no 10 
,----, r-----, 3.0 ,..---, 
15 
RIF 1.5 
10 
5 
0.0 a 
Tmax 
(h) 
-
Fig. 14 Bioavailability 
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Table 18. Bioe uivalence results of stud 
AUC 
Study 
Medianl Point 
Estimate 
93.66 
95.94 
97.85 
84.59 
92.77 
90.89 
Testl 
Ratio 
1.00 
1 
1 
Rifam 
1.00 
.t'fo,rocol Results 
90% 
Confidence 
Interval 
11.38 
84.19-109.38 
86.43-111.83 
78.63-91.05 
88.15-99.49 
87.27-98.33 
57 
% Span 
11 
11 
objective of the study was to bioavailability in healthy 
Rifafour E275 fixed combination tablet consisting, of rifampicin, lo:tU;llla..I:.IU, 
and ethambutol as a to, the reference of 
nt~lmt)lC1n. isoniazid, ethambutol, as a single second 
nu,prnrl" was to establish dose combination Rifafour 
combination is bioequivalent to the 
in the reference products. 
study concluded (Fig 15), 
all paI'amerers Cmax, AUCT 
to the reference product. 
a.IvJl1'VV results (Table 1 
required limits for Cmax, and 
was no statistical SH!mtJlcaltlt 
for INH, RIF, PZA and 
57 
confidence 
for the 
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;~ 
ETB. The product formulation was declared successful based on both 
bioavailability and bioequivalence data. 
Study 13 
1. 5 6.0 ,---------, 
4.5 
4.5 
INH 1.0 
3.0 
3.0 
0.5 1.5 1.5 
no no no 
~-~ ~-~ ~-~ 
RIF 
2.5 
2.0 
1.5 
1.0 
0.5 
0.0 
PZA 1.5 
0.0 
3.0 
1.5 
O.n 
T 
Tmax 
(h) 
15. Bioavailability 
10 
5 
o 
40 
30 
20 
10 
o 
3.0 
1.5 
nn 
-
Cmax 
(mg/l) 
3.0 
1.5 
0.0 
6 
3 
6 
3 
o 
of study 13 
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TI/2 
(h) 
Test 
25 
20 
15 
10 
80~--------~ 
70 
60 
50 
40 
525 
450 
375 
300 
r--------~ 17.5. 
15.0 
12.5 
10.0 
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(rng.hlI) 
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T bl 19 B' . 1 a e . loeqUlva ence resu ts 0 f d 13 stu ly 
Study 13 Medianl Point Testl 90% % Span 
N=24 Estimate Reference Confidence 
HV Ratio Interval 
Isoniazid (INH) 
Cmax 92.80 0.97 82.3-10S.1 22.8 
AUC 100.4 l.06 91.0-111.2 
AUCI 101.4 1.07 91.7-111.7 20.0 
Rifampicin (RIF) 
Cmax 91.5 0.95 8S.S-100.8 1 
0.95 87.0-97.8 10.8 
• 
AUCI 
• 
92.6 
• 
0.94 87.1-97.4 10.3 
Pyrazinamide (PZA) 
Cmax 100.2 1 96.0-106.0 
.AUC 98.8 1.00 9S.4-103.0 7.6 
AUCI 98.4 1.00 94.6-102.7 8.1 
Ethambutol (ETB) 
Cmax 100.4 1.15 84.1-118.S 34.4 
AUC 96.8 1.21 8S.3-113.7 28.4 
AUCI 102.9 1.~8 86.6-120.8 ~ 
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Summary of bioavailability and bioequivalence of studies 
gives an assessment 13 studies. The ,",UTYlnrU 
."' ... ''"'u ........ "'I ... l ... ,'~ the outcome are defined below and 
protocol investigation based on the results. 
./= No significant difference bioavailability data and within 90% 
confidence interval of 80-1 bioequivalence analysis. 
t- Test (parametric) Signed rank Test (non 
bioavailability was 
X= Significant data and 
confidence interval bioequivalence analysis. 
60 
Student -
for 
x./= Dissimilar results for T est (parametric) and Wilcoxon Signed 
rank Test (non bioavailability 
to define overall study conclusion 
not 
Bioavailability 
60 
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results 
AUC 
./ 
./ 
./ 
./ ./ 
x ./ 
x 
./ 
./ ./ 
./ 
x 
./ ./ ./ x 
./ ./ ./ ./ ./ 
4 ./ ./ ./ 
./ 
./ 
5 ./ 
./ ./ ./ ./ x 
6 RIF ./ ./ ./ ./ 
7 INH ./ ./ ./ ./ 
RIF ./ ./ ./ ./ 
./ 
./ 
./ 
./ ./ 
9 INH ./ x 
RIF x X 
10 INH X 
RIF ./ 
./ x 
1 ./ ./ 
RIF ./ ./ ./ ./ 
12 INH ./ ./ ./ ./ 
X 
13 
./ ./ 
ETB ./ ./ ./ ./ ./ 
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3.3 Conclusion of studies using extended time protocol 
62 
Information obtained from bioavailability data from the respective studies 
presented in Figures 2-15 and Tables 6-19 for bioequivalence together with 
summary Table 20 were used to determine the outcome of each study 
investigated. 
In conclusion, 13 studies that each consisted of test and reference products were 
investigated. Eight studies were declared successful based on both bioavaiiability 
and bioequivalence results. These studies were, Study 2, 5, 6, 7, 8, 11, 12 and 
13. Three studies were declared successful based only on bioavailability results, as 
the bioequivalence results did not comply with the necessary confidence interval 
limit of 80-125%, as required. One study, Study 10 was declared successful based 
only on bioequivalence, as the reference and test products were both 
bioavailable, but statistically significantly different with respect to INH. Study 9 
was declared not a successful product, as the drugs were bioavailable within the 
required limits, but statistically significantly different when comparing the test to 
reference products. The bioequivalence results for Study 9 was also outside the 
desired confidence limit of 80-125% for RIF, rendering the test product 
formulation unsuccessful. 
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Chapter 4 
Minimum Points Protocol ....... ...,"" ... u ... "" 
4.1 Introduction 
In this results obtained the time protocol schedule presented 
Chapter 2 (Table 5) were used to the minimum point schedule. 
15 time extended time (phase 1 analysis) presentea in Chapter 3 ",v ... ",,,.,,, ..... 
(0, 1 1 2, 8.0, 1 48.0). This is 
points 
mImmum 
minimum time point protocol (phase 2) that of 11 time 
(0, 0.25, 0.5, 1.0, 1.5, 3.0, 4.0, 6.0, 8.0) and the phase 3 
protocol that consists 6 time points (0, 1.0, 6.0, 8.0). 
The data is presented in graphic to provide a HVU"U", and ease 
Bioavailability and bioequivalence 
data obtained in Chapter 3 as well as derived conclusion 
to determine 
For the 
as a finger print 
conclusions. optimum minimum time protocol to derive ., ... " .. "'. 
of the investigation this chapter, only ,,",UJ'u..tlo., AVCT, AVCr 
were ..... Vi .• ;)' .......... , both bioavailability bioequivalence 
4.2 Graphic of phase 1,2 3 time protocol 
Fig 18 (Study is used as an example to give a descriptive and template 
of the graphic information of all the investigated. investigated 
within a study compnses panels from left to 
(mg/l), and for both bioavailability and 
Cmax(mg/l) 
information. 
left and centre 
the centre panel 
For bioequivalence the base of the 
the 125%. 
deal with bioavailability infonnation 
with AVCT(mg.hll) and AVCI(mg.hll) 
as 80% upper limit of 
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with standard error of 
bar and clear test bar. 
64 
mean indications are represented by a 
set of bar represents phase 1, 2 
3 protocols from left to right within each panel .. .:>"".:>r'1"''l1.:>I" 
bioequivalence information follows same 
bioequivalence the bar has to fall within the limits 
upper limit of 125%. Each bar represented has an 
acceptable 
panel and the 
and lower 
denotes the percentage span. The mid point 
estimate value. 
Study 1 
summary phase 2 and phase 3 analysis 
1 (Rifinah 300) that investigated two n.fl';:> .. .:>" 
each IS ... '"' •. un ..... as 
1.1 ................... 150) and Study 
a 
results: both Study 1.1 and Study 1 16 and 17), 
comparable bioavailability for all investigated being 
and AUCI with no significant difference to the The phase 
2 represents the desired minimum time points as points 
in Study 1.1 and Study 1.2 in phase 1 went up to a maximum 
64 
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7 
6 
5 
4 :" 
3 
18 
16 
14 
12 
10 
8 
PI P2 
Cmax 
(mg/I) 
Study 1-1 
30 
-. 25 
• 
L. '-
P3 
'- '----
'- '---
AUCT AUCI 
(mg.hlI) 
20 
I 
80 
70 
60 
50 
_ Reference Test 
125 
100 
I 125 
100 
Cmax Auer AUCI 
Confidence Interval (Ofo) 
Bioequivalence 
Fig 16. Bioavailability and bioequivalence "" ....... ""..., all phases study 1.1 
65 
two assumptions for the bioequivalence analysis in phase 1 (Chapter 3) were 
applied: (1) that received period one the test 
drug period two, and that, (2) for purposes of the the 
subjects the drug order .. ",1"''''r''',''''''''' then test and the seC4:ma eight 
received it the reverse The bioequivalence for Study 1.1 and 1.2 
In 2 was within limits for ameteJrs of Cmax , and 
bio-inequivalence was shown for all parameters in phase 2 Study 
1.1 and 1 
product formulation was ;:)U...,...,,,,;:);:)!Ul based on comparable bioavailability only, 
yielding results In both phases and consistently complied with the 
bioequivalence limits With respect to 1.1 and 1.2 (Fig 16 
65 
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17), RIF ameters Cmax, fall within the 
limits ""V'_\.I'.U a',,'"vv to be acceptable across the various phases 
Study 1-2 
7 30 
125 
6 
INH 25 
5 100 
4 20 
3 LML1~'---' 
18 
16 
RIF 14 
12 
10 
8 
Fig 17 
(mg/I) 
r--------=---=--, 
80 
70 
60 
J 50 
Pl P2 P3 PI piPJ 
AUCT AUC! 
(mg.hlI) 
_ Reference 
- 125 
100 
lt3 LU 
Cmax AUCT AUCI 
Confidence Interval (°/ .. ) 
,""::un .. ",::::. •. .., ...... ,,,,, results all study 1.2 
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Study 2 
r--------, ,---------, 25 
4,0 
20 
15 INH 3,5. 
~. :0 3,0 
2,5 
14 """"'.....,.,.~......, ~-------
12 
10 
8 
6 
~ I 
o UIRLl_LL-JIILl-LJ 
40 ,----------, 
35 
30 
PZA 25 
20 
15 
10 
5 
o 
3.5 
3,0 
2,5 
2,0 
~--......, 
Cmax AUCI 
(mg/I) (mg.hlI) 
75 
60 
45 
30 
600 
450 
300 
150 
16 
12 ~ 
8 E , __ 
Cmax Auer AUCI 
125 
• 100 
125 
125 
100 
125 
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I 
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Bioequivalence 
Fig 18 Bioavailability bioequivalence results all phases study 2 
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Study 2 
In summary phase 2 and phase 3 analysis of Study 2 (Myrin-P) (figure 18) 
demonstrated comparable bioavailability for for all 4 with no 
significant to the and to that 1 The results 
INH AVCT and were significantly different across phases 
and reflect extended time point results. Bioavailability for and AVCI 
results for and ETB showed no significant across 
phases the apparent values are in phase 3. AVCI 
values consistent across whereas those for ETB 
dropped relatively, but were not significantly different to the phase 3. 
PZA showed no significant for the across the phases 
investigated. PZA consistent difference from phase 
1 to phase but no significant difference in phase 3 using the nnrumum 
points. apparent PZA value is also lower to that of 1 and 
phase 2 as to to 
The bioequivalence analysis was within limits 
different phases on the established criteria. 
out of the ... v.u.y, .... u,~ .... limits 1 In phase 2 
Cmax of INH across the 
was marginally 
3 the values were within 
AVCI 
limits, but not phase 2 and 3. 
phase 1 bioequivalence values were within 
and PZA all parameters (Cmax, AVCT 
and AVCI) were within the COImOlen(;e limit for 
Cmax was the AVCT 
phase 1, 
marginally out on the 
end confidence Bio-inequivalence was shown based on 
AVCI. In phase 2 showed bioequivalence for parameters. 3 
results yielded bio-inequivalence based on AVCT were 
marginally out at 
the interval 
bottom end interval and AVCI to the upper end of 
68 
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1 results v ',",lU~U test formulation successful relative to the 
rAt.<>r.:>1"Il"'''' product, on bioavailability and bioequivalence. 2 and 
phase 3 had comparable results for bioavailability. ...,llllllCU results across phases 
were also registered to for RIP and with 
phase 3 that "Iv\u"'r! bio-inequivalence. The AveT 
was however marginally out at lower end interval. 
Study 3 
6 L IJ 125 
INH 5:'" 
25 ~ 20 
100 
4 
i 15 
3~ _____ ~ ____________ ~ 
125 
9 40 
35 
8 - 100 
30 
7 i 
,-------
45 125 
450 
40 300 100 
150 i 
35 
Cmax Cmax AUCT AUCI 
(mg/I) 
_ Reference D Test Confidence Interval (%) 
Bioequivalence 
Bioavailability bioequivalence results all u.u.Q • .::. .... .::. study 3 
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Study 3 
In summary (Fig 19), the phase 2 and phase 3 analysis of Study 3 (Rifcin 
demonstrated consistent 
formulation Chr\Ul~·t1 slightly 
on all 
for Cmax 
The test 
to the reference 
throughout, with 
signifi cantly 
exception of INH that was higher but showed statistically 
to that of the This was <:>nn.<:>r .. :n1" across all phases. 
INH, AUCI were consistent across phases showing a 
'IT",,''''''''''' to that of the 1"",1',,,, .. ,,,,,,,..,,, based on the parametric test but not 
for the non-parametric test, which gave p-values of 0.07 and 0.06 for AUCT and 
AUCI, respectively, phase 1 and but a significant for 
AUCT and AUCI in phase 3 where the were less 
Rifampicin showed a significant difference for both AUCT and in phase 2 
consistent but not in 
bioavailability across 
while pyrazinamide showed 
2 and phase 3. 
<,u,",'''V,", was shown completely 
for phase 2 and 3, but not for 
for the parameters Cmax and 
RIP showed consistent bio-
inequivalence across 1J110C':>'-''' and across par'ameters in phase 2 that 
showed m 1. conclusion with 'l"PCT'''''(,1' to phase 
one remams that the product was successful as bioavailability was 
the bioequivalence was unsuccessful 
with respect to and PZA being 
70 
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summary (Fig 20) 
demonstrated cOlmpara;b 
phase 2 and 
bioavailability on 
Protocol Results 71 
3 analysis of 4 (Rifcin Co) 
to Cmax drugs with rl'>t~'rl'>n 
was not significantly different to that the reference with the exception of 
in phase 3 that showed a significant rI,'fb:.,.,,,,nr·,,,, 
With respect to and PZA no significant 
across phases. There was a in AUCT values in phase 3 of 
and PZ~ but the AUCI values remained consistent across 
phases. For RIF, AUCT showed a difference 1 and 
but not in 3 with 
points were .. nu"..,...,...... values 
1.111"''''''''' with no "'SlHLJl"'UJlU difference. 
71 
values mmtmum 
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Study 4 
4.0 
INH 3.5 
3.0 
2.5 .---~ __ '-_ ~ '- '- L 
9 
B 
RIF 7 
6 
5 
4 
40 
PZA 
AVCI 
-
18 
16 
14 
12 
40 
35 
30 
400 • 
125 
~ 100 
-='::::.!:::.'::="::::....J 
123 
CmIlX Aver AVe! 
125 
100 
125 
100 
Confidence Inten"al ("/0) 
Fig 20. Bioavailability bioequivalence results all phases study 4 
Bio.equivalence was 90% confidence ,-,UJ'''''''-. AUCT, 
72 
and PZA across V"""'''''' investigated. 
all parameters. 
"hl',,".u)ri bio-inequivalence 
C013s1:;termv across all V"""",," 
conclusion summary is consistent, adequate comparable 
bioavailability for the formulation with to Cmax, making 
formulation successful. ..... nu' .. ''' .. , based on the 01o-1m~aulvalenice of 
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the COImOlem;;e interval the lower vVIU1U''''11\~V interval as required, the 
test was found to unsuccessful. 
10 -
10 
9 
8 
7 
6 
5 
4 
Study 5 
PI P2 P3 PI P2 P3 
AueI 
(mg/I) (mg.hiI) 
Reference Test 
50 125 
45 
40 100 
35 
40 125 
35 
30 100 
25 
123 123 
Cmax Auer AueI 
Confidence Interval 
Fig 21. and bioequivalence results all phases study 5 
Study 5 
In summary 21) the phase 2 3 Study 5 (Rifcin ) 
derTIOllstl-at<::d bioavailability for both INH and RIF AUCT and AUCL 
Bioequivalence was shown for INH consistently for all 1.11"""''''''' and all 
Bioequivalence was also shown for the and AUCI paname:ters 
across phases 1 to RIF for phase 1 2 
being marginally out at the lower confidence interval, but not in phase 3 where 
bioequivalence was registered. 
73 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Chapter 4 Minimum Time Protocol .. "',,"u.· .. , 74 
conclusion sUl1t1m:ary IS consistent with that of the extemlea time 
protocol 
bioequivalence. 
successful product formulation based on bioavailability and 
22. Bioavailability and bioequivalence 
Study 6 
summary the phase 2 and phase 3 
demonstrated consistently bioavailability 
lHUCHU1Vll of Rimactane across phases 2 
marginally 
Cmax 
that of 
using the 1U"AU .. \.4,,1 
..,,, ... u.~ ... all phases study 6 
of Study 6 (Rifadin) 
to that reference 
of the test was 
different to 
protocol in 3 presents 
a lower but not significantly different both test and rAh-rA" This also 
a lower in phase 3 not a Slgruncarltlv different 
AVCI remained consistently across all fJu .... ..,""» Bioequivalence was shown 
for and AVCI across all conclusion remained 
VUJ""",....,J", in that the product formulation was successful on bioavailability 
bioequivalence. 
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Bioavailability bioequivalence results all phases study 7 
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Study 7 
In summary (Fig 23) the phase 2 and 3 analysis of Study 7 (Rifafour) 
bioavailability consistently across 
difference to reference 
no 
parameters measured. 
Bioequivalence was satisfactorily complied with for all parameters of Cmax, 
AUCT AUCI and for all drugs INH, ETB exception 
Cmax phase 3 was out on the upper of the limit. 
conclusion across phases remains consistent in that the product 
formulation was successful on both bioavailability and bioequivalence. 
Study 8 
In summary 24), the phase 2 and phase 3 of Study 8 (WHO) assayed 
for only RIF and DRIF but consisting of a drug combination and 
PZA, bioavailability and metabolite DRIF under 
parameters AUCT and across all mean 
average for for the test product was marginally higher and than the 
reference not significantly different. AUCT was lower 
in phase 3 to minimum used but not significantly for both 
the mel:aO()lUe DRIF. AUCI values were also consistent not 
significantly rhttp.rpnt 
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Study 8 
14,------, 
12 
10 
8 
6 
4 
2 
o 
1.2 
1.0 
0.8 PI '-P2 -'P3 '-PI ~ P2 '-P3 
Cmax AUCT AUCI 
(mg/l) (mg.hlI) 
_ Reference Test 
Bioavailability 
Bioavailability bioequivalence 
Bioequivalence analysis was satisfactory for 
was within for Cmax 
80 
125 
70 
60 
50 
15 125 
10 
-- 100 
5 
123 
Cmax AUCT AUCI 
Confidence Interval (GA.) 
'."';'"Jl~" all phases 8 
1 phase 2, but 
out·on upper limit on the lower limit for AUCI. For 
77 
3, 
Cmax and AUCT were marginally out on the upper limit and AUCI on lower 
limit. conclusion surnmary is thus consistent the parent drug 
':>U"",,,",,,",':>':>"'UI across 
and 
across all phases, although 
lU .... Jl"LH.JU based on 
analysis was 
convincingly than 
77 
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Study 9 
summary (Fig the phase 2 and phase 3 of Study 9 (Rifinah Ped) 
',"'>I.V"L bioavailability INH across 
AUCT not significantly different and that 
showing a consistent significantly different result. RIF Cmax , 
Fig 
result across 
9 
6 ,------, ,--------
5 I 
4 :r: 
3 
2 
25 
.20 
o LIIII.Ll.....JIIILl-JIlJCLJ 15 
--------, 
16 -" 80 
14 
12 
10 
8 
Cmax 
(mg/I) 
AUCT 
(mg.hlI) 
_ Reference 
70 
60 
50 
Cmax AVCT AveI 
Confidence Interval (%) 
Bioavailability and bioequivalence results phases 
Cmax 
and 
125 
125 
100 
9 
was satisfactory INH in and AUCI but not for 
Cmax across the three phases. All parameters for RIF showed bio-inequivalence 
across phases. 
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conclusion summary with the extended time protocol to that of phase 2 and 
3 remains consistent in that the product formulation as a whole was 
"",_..,,,,""","U based on bioavailability only not on bioequivalence due to 
Study 
26) the phase 2 3 analysis of Study 10 (Rifater 
consistent bioavailability for both RIF and PZA with no significant 
in the average mean relative to 
INH showed consistently 
reference in Cmax across an 
across all phases as as 
showing a significant difference between test f"Pt'''f"Plr'1f'P across all 
for RIP were ,,"ULJ'BU,' 
due to the mInImUm 
across only AUCT 
""'1.1";;;\11.41";;; In phase 3. No significant 
rhT~;:'f","'nr'''' was "n." ... """"" for UIVaV(UHl.UIH and AUCI for RIF but for 
across 
PZA these parameters was consistently significantly different 
,",H''''''''''_ but similar. 
bioequivalence analysis was within the 
and PZA across all was 
AUCI with bio-inequivalence across all phases for The 
the consistent with product 
successful based on and bioequivalence. 
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Study 10 
7 35 
6 125 
5 30 
INH 4 25 
3 100 
2 ~ 20 BBBB~B 0 ,- '- - '-- 15 
90 
16 125 
14 i 75 
RIF 
12 100 60 
10 
45 
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600 ~~~BBBB~~ 125 45 PZA 450 
40 100 300 
35 
• 
I~ U 150 
1 2 3 
Cmax AUCI Cmax Aver Ava 
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_ Reference D Test Confidence Interval (%) 
Bioequivalence 
Fig 26. Bioavailability bioequivalence results phases study 10 
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11 
In (Fig 27) phase 2 and 3 analysis of Study 11 (Rifinah 
1501150) demonstrated consistent bioavailability and was for all 
param.eters for both and RIF across allIJHu" .... ". 
Bioequivalence was also consistently and adequately achieved within the 
'"'v ........ "'u,_'"' interval for both 
summary conclusion IS 
succeS:SIUl for both 
and RIF on Cmax, 
product 
and bioequivalence. 
Study 11 
and AVC!. The 
HIU.IC1.LJLVll making it 
16 ~~~-, ,----------, 
70 
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12 
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8 
14 
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Bioavailability 
Fig 27. Bioavailability and 
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Study 12 
In SUITlmary the 2 3 analysis 12 (Rifinah 150175) 
demonstrated consistent bioavailability for INH across aU phases that was not 
significantly ttAr'",,,,r for Cmax to the reference product. RIF Cmax was 
also consistently significantly different across all phases, 
For both were vv.""'.,,. ..... , .. across phases 
not slgmnCarltly the exception AUCT that 
showed a ..>,!">uu.,."uu difference in 3. 
Study 12 
7 ,-------, .------------, 
6 
INH 
5 
4 ~ 
18 
16 
RIF 14 
12 
10 
8 
Fig 28. 
I 
(mg/I) 
AUCT 
(mg.hiI) 
_ Reference 
BioavailabiHty 
and bioequivalence 
Bio'equivalence was consistently "" ... ",u.", .. ,n 
both drugs across phases, but not 
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across phases both The conclusion 
formulation was successful and consistent 
the product 
all phases based on both 
bioavailability and bioequivalence. 
Study 13 
:: I~ ~~~~~~~- 100 5~ 4 INH 3 
- 25 125 
2 ,--__ -, .-_'-__ '--_'-_-__ '-----, 80 [' 
12 70 
60 
50 
10 !:: ! ~~~B~~B~~ ,100 
RIF 
125 
8 L..RLL-"LL'-"'~..I...l 
40 ,----------::1 600 ,-------.., 
125 
PZA 450 
35 
1- 1_ 
3.0 125 
ETB 2.5 i 
2.0 
U2 
Cmax AVCT AveI Cmnx AVCT Avcr 
(mg/l) 
-
Confidence Interval (%) 
Fig 29. Bioavailability and U.LVJl.l"'...., results allv.luJ,"'V.:I study 13 
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29) phase 2 and 3 analysis of 13 (Rifafour 
Study 
summary 
demonstrated v"''"' ....... " ....... bioavailability for all investigated all 
parameters, showing no significant difference to of the across all 
apparent values for were lower in phase 3 
to the minimum points schedule. 
Th~ bioequivalence was also within the limits for all parameters 
Cmax, AUCT and across all for all the investigated with the 
exception Cmax for ETB that was marginally out on the lower limit of the 
confidence interval in phase 3 conclusion across 
is thus consistent making product formulation successful in terms 
both bioavailability and bioequivalence. 
4.3 Discussion and Conclusion 
With ,.",,,,,,,,,,,''1" to the studies investigated for all drugs within a study and 
across all the phases it is apparent that bioequivalence analysis is a sensitive simple 
tool to assess overall quality studies to determine the ............... .. 
time points needed for such investigations. F or a given formulation, the 
pharmacokinetic of Cmax, and AUCI, across phases 
investigated, consistency in the outcome of the results. 
For bioavailability, data 
across all phases 
Cmax, AUCT 
was generated for Cmax, half-life, 
for all drugs only the DaramClc;rs 
were in the graphic form. 
and 
importance, 
What is important been achieved in this study, is that Cmax drug 
concentration in all 3 phases within (therapeutic 
as set out literature and presented in Table 4. second point that has 
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been is when COlnPlirm extended to minimum time 
evaluation across is maintained to ensure conclusions can be 
with to the quality the product investigated. has 
ensured the optimum time were derived. on 
observations it IS evident that the time protocol does not provide 
a quality of data that .. AU ...... '",,, time 
The IIJl(J,~"" presented Chapter 3 6-19) the extended 
protocol that all pharmacokinetic parameters, remained remarkably 
similar across all parameters across all phases in general. In particular, a high 
level consistency was found when comparing phase 1 and phase 2 
protocols all pharmacokinetic indicating acceptability the 
2 minimum points ..... rrnnl'n' 
Observation from the data of respective showed 
more especially AUCT, yielded the best results consistently. It is clear that 
In general AUCT data remained same for 1 and 2 and that 
3 bar charts as expected were lower magnitude, relatively, due to the only 6 
points being used. 
For data in general with respect to phase 1, 2 and 3 bar graph 
as by the second panel in in this chapter, 
constant in where and PZA are in the fixed-dose drug 
combination. This is however not the case INH and are present 
the as observed the graph is constant for 1 
and 2, but not phase 3, where the general drop in the magnitude these 
bar graphs is observed. In the where DRIF was measured was also an 
shift in the observed magnitude bar chart in phase 3. 
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2 time protocol in general thus provides 
conclusions to those of the extended 
and AUCI for both bioavailability 
optimum time points to 
protocol with respect to 
this finding is that the protocol can contribute u".,,,,,-,, 
assessment. 
establishing 
is cost effective in the ~UI"v"'U number "' ..... ,,1-", .... "'. the a policy 
number the potential 
." .. ,,,,,.:."'<... assessment. Based on current 
\.jUJl\Jfi..'\Jl turn ",rnel1"n 
be satisfactory in H1V'............ for 
combination bioequivalence testing and is CUIHPi:UlUlVt: to the 
that is currently in use. This would hopefully serve as 
pharmaceutical industry to manufacture 
The phase 3 protocol, from general observations seemed to be acceptable 
i:JtUUll;;;i:J but was not consistent with results 
2 protocols some of the product formulations 
1 
the case 
assessment 
of 
3 to 
could 
results. This 
restricted time points utilised. 
... "."''''' .... be utilised for ongoing quality assurance 
after a combination has been registered by the 
regulatory could be explored are establishing 
whether CmaxiAUC andlor CmaxiAUCI ratios could potentially yield a more 
reliable level of consistency phase 3 time points schedule in mind. 
In conclusion, the ",tU\.lll;i", ...... ,. .• 1">«.",.. covered different variables that included, 
fixed-dose drug combinations and formulations from different manufactures. 
formulations consisted of and The subject 
ranged from to and also different sex. 
Studies were as patients. One study (Fig 
(Study 8) and metabolite. 
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pointers the discussion and conclusion of this and also 
into account, it is that the methodology was 
appJied to determine the optimum minimum time was acceptable. The 
bioavaHability of Cmax, and AVCI were ",...r·o""·,,, 
for the intended investigation to show comparable bioavailability test 
relative to respective in all phases. the 
pharmacokinetic as be used successfully to 
if similar quality of the drug formulation was 
1"""''''-1>10 to utilizing phase 2, but not phase 3 H"ll11..",I1 
time point protocol "'..,.,,"''''' .... '''. 
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11'1""' ........... ,.. 5 
Correlation, Sub-Group and Reduced Subject Analysis 
Correlation analysis 
," .. ",rrnan--r-comelatlon analysis was using all data over the 13 
studies for the INH, RlF, The data was used regardless 
whether the drug was administered as a FDC or individual formulation. 
described in Chapter 4 and based on the observations and VVLj'VIY"'VI." 
protocol with '-'V" ........ H. mmlmum was 2 0.5, 1.0, 
1 2.5, 3.0, 8.0). The aim of the correlation analysis was to provide 
added support and thereby verifY phase 2 as the optimum minimum time points 
schedule. The correlation was r"'''Tr1I'T,'''''' to 
parameters. 
1 and 2 pharmacokinetic 
Table 21 describes companson respective pharmacokinetic results 
presented in all the studies and reinforces findings in Chapter 
Table 21. Correlation Table of phase 2 
Phase 1 2 
Cmax Cmax AVCT 
vs vs vs vs vs Vs 
AVCT AVCI AVCT AVCI AVCI 
0.87 0.87 1.00 0.90 0.86 0.98 
0.81 0.79 0.90 0.91 
0.94 1.00 0.96 0.96 
0.99 0.99 1.00 0.99 0.99 1.00 
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The analysis shows that overall there is good agreement between the Cmax, 
AVCT and AVCI correlation values. This implies that data obtained with a 
lesser time point schedule with 11 time points (phase 2), compares well with 
results obtained using the extended 15 time point schedule (phase 1). 
The best correlation is however defined by AVCT vs AVCI in both phase 1 and 
phase 2 confirming the statistical package to determine similar outcomes with 
fewer time points. The observation, in increasing order of improvement of 
correlation in both phases and across all drugs investigated is, Cmax vs AVCT, 
Cmax vs AVCI and AVCT vs AVCI. It is also apparent that by optimising the 
time protocol, in this case phase 2, there is an inherent improvement in the quality 
of the data as shown by the Spearman correlation coefficient (Table 21). The 
correlation with specific reference to Cmax vs AVCT in both phases and for drugs 
INH, RIF, PZA and ETB is improved from 0.87, 0.81, 0.95 and 0.99, to 0.90, 
0.90, 0.96 and 0.99, respectively. 
If it is considered that phase 1 time protocol is presently considered as the "gold" 
standard, then it becomes appropriate to compare phase 2 as the recommended 
optimum time protocol to that of phase 1, thereby giving additional justification 
for phase 2 time protocol's acceptability with respect to Cmax, AVCT and AVCI. 
Table 22 illustrates, by means of the Spearman-r-correlation, the relationship 
between phase 1 and phase 2 with respect to the given pharmacokinetic 
parameters. 
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Table 22. Correlation Analysis comva.d::'VH of phasel and nhase2 parameters 
Phase 2 
Phgsel AUCT AVCI 
INH Cmax 1.00 0.90 0.86 
AVCT 0.87 0.99 0.99 
AUCI 0.87 0.98 0.99 
RIF Cmax 0.98 0.8 .77 
AVCT 0.82 0.96 0.97 
AVCI 0.80 0.95 0.97 
PZA Cmax 1.00 0.95 0.93 
AVCT 0.93 0.94 A.96 
AVCI 0.93 0.93 0.96 
ETB Cmax 0.99 0.99 0.98 
AVCT 0.99 0.99 0.99 
AVCI 0.98 0.99 0.98 
analysis 
phase 1 and 
on Spearman "' .... ',.va coefficient for comparison of 
2 shows that is good agreement each of the 
parameters of Cmax, AUCT and AUC!. further confirms that mInImUm 
time protocol can be viewed as u.vv' ..... ntJ'uL .... 
(phase2) data to (phasel) results 
yielded better 
the comparison 
than that of (phase 2) vs Cmax (phase 1). The 
correlation values were 0.90, 0.88, 0.95, and 0.99 for the AUCT 
PZA and ETB """""""'''''''' and 0.86,0.77, 0,93 and 0.98 reSloeCtn 
(phase 2) versus (phase 1) 
RIF, 
Aue!. 
for The use of 
extrapolation minimum times points to confirm Cmax L ..... ",U'-'U where 
regulatory approval has been achieved 
Comparison of (phase 2) to 
correlation coe~m(:1ents for all drugs, the 
90 
extended 15 time point protocoL 
1 AUCT and AUCr 
being 0.87, 
lower 
and 0.99 
, 
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PZA and respectively, 0.80, and 
0.98 
ofINH, 
of the 4 respectively. support optimum 
minimum time points to be that 
4.0, 6.0, 8.0. 
5.2 Sub-Group analysis 
2, namely 0, 0.5, 1.0, 1.5, 
Sub-group analysis was to compare pharmacokinetic parameters 
individual formulations to nXj~a-,a05;e combination drug formulations, healthy 
to and to the 
par'amere.rs between the sexes. Phase 2 time .... r".""I'''1 data was 
investigation. 
5.2.1 Comparison of individual to combined formulations 
in this part 
comparison of individual r",t'''r",~, ... ",l data to the combined test 
(T) formulation for the studies in the set, aimed to the overall 
comparative bioavailability of nX4~a-'a05;e drug combination .... v ... n ...... "'j ... "', relative 
to individual drug 1"", .... ,,1'11'1 
Table summarises this miiJmlatllon using the pharmacokinetic parameters of 
AUCT and , .. ....,""-' .... The table ret1j~cts the mean and standard error of 
the mean (SEM) for the individual (reference) products and combined 
(test), The tests to determine significant differences 
were the paired t-test (Test 1) and pairs test 
Significance was declared the p-values obtained were 
0.05. 
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Table 23. versus 
Isoniazid 
AVCT 
~T R T R T 
Mean 21.70 
SEM 0.75 1.06 1.06 
Test 1 0.59 0.88 
Test 2 0.47 
R R T R T 
Mean 13.03 11 51.60 49.33 67.96 17 
SEM 
Test 1 
Test 2 
Cmax 
R 
38.62 39.34 460.12 486.98 
0.73 0.74 10.88 10.66 11.22 20.09 
Test 1 0.29 0.43 0.15 
Test 2 p= 0.09 0.35 0.53 
Cmax AVCI 
R 
3 
0.73 0.64 0.69 
0.91 0.94 0.99 
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concludes Cmax values INH and were significantly higher 
for the r""i-,:>r""I"1"'''' product than test. For these values were 6.06 mg/1 
5.61 mg/1 reference and test respectively. AUCT of INH 
21. 70 the and test v ...... "'.'" respectively were not 
significantly The AUCI followed a trend. the 
values were 13.03 mg/1 11.98 mg/I 
test respectively. RIF a similar to that Cmax was for 
(51,60 and 49.33 and (67.96 mg.hJI 67.17 
mg.hJI), differences were not significant. The Cmax , and AVCI 
values and were similar for reference values, no 
.>1/'; .. "'-'" .... ,,. differences between the pharmacokinetic of the and 
test products. 
findings imply that although formulations investigated were bioavailable 
isoniazid concentrations generally ~thin the recommended 
therapeutic range, there is a statistical significantly difference on the overall 
set investigated. The outcome that the drug combinations 
yield statistically significantly lower isoniazid and rifampicin than the 
individual (reference) 
implications for both 
This reduction 
individual as well as for national tuberculosis 
programmes due to potential for treatment failure and selection of 
mutants For and the were comparable 
of whether the respective 
combined (test) formulations. This finding is 
were in individual (reference) or 
the prospect fixed-
dose formulations with r"''''''''I"'1" to pyrazinamide and ethambutol. 
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Comparison of females versus 
of sex on bioavailability was 
olunteers and were considered to be a common Table 
summarises information using the pharmacokinetic parameters of 
94 
AUCT The table the mean values and standard error of the 
mean (SEM) for and results, The tests used to 
determine differences were the paired t-test 1) the Wilcoxon 
matched signed (Test 2). Significance was declared p-
obtained were 0.05 . 
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Table data 
Isoniazid 
Cmax AUCT AUCI 
Female ale Male 'Female Male 
Mean 5.6 .77 20.46 30.06 
SEM 0.23 . 0.18 0.98 0.65 1.32 0.90 
Test 1 0.05 
2 0.50 0.11 ' 
AUCI 
Female Male Female Male 
45.18 36.69 350.17 .68 545.45 447.07 
7.39 
p= 0.06 
Ethambutol 
c 
emale Female Male Female Male 
Mean 3.18 3 10.61 12.44 10.99 
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Table 24 concludes that females attained 
Reduced Subject Analysis 
---C----J higher Cmax values (6.27 
96 
than (5 mg/l) dltlten:mcles were not significant. AUCT and 
AUCI values followed a similar trend in that female values were slightly higher but 
not significantly different. 
and values were also marginally higher females aU parameters 
(Cmax, and AUCI), with the AUCT PZA, the 
differences were slgmhcarlt. The values for were similar, females 
.18 mg/I) for (3.20 mg/l) with no significant differences. The AUCT 
and were also similar and not significantly different. 
findings show that females attain concentration rifampicin 
pyrazinamide that is statistically rl1tt'i:>t"",nt to that of males. The observation 
becomes important in deciding on an ",n-"'('1"11"'" dosing to a 
outcome in males and females. For isoniazid and ethambutol there was no 
statistical difference in the data and the values were comparable for males and 
"",u, ... "",,,, and within recommended clinical range. 
5.2.3 Comparison of healthy volunteers versus patients 
The comparison of subjects healthy volunteers (H) 
to that of being patients (P), regardless of sex status. The statistical tests applied 
to the bioavailability were the unpaired t-test 1) and the Mann Whitney 
test mean data 471 
compared to that of 126 patients. 25 summarises 
pharmacokinetic parameters Cmax, and AUCI. 
mean error the mean (SEM) 
96 
volunteers were 
information for 
table 
the 
the 
of healthy 
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volunteers respectively. Significance was declared when the 
obtained were less than 
The ""0."",,.,, in Table that there is a significant difference when 
comparing the For INH healthy volunteers attained a 
values for mg/I to 6.19 mg/l, 
compared to mg/I respectively). This 
The inverse was noted for RIF 
mean values were lower; 8.61 mg/I compared to 13 
This finding is certainly to increased rifampicin metabolism by 
auto enzyme induction that would experienced by patient who would 
have rifampicin prior being on the clinical trial [42, 44, 51 58, 
100]. All results were statistically significant. The were within clinical 
No studies were done, where was administered to patients the 
comparison to healthy volunteers could not determined within the realm 
studies investigated. 
results two of subjects, that is healthy 
and patients. It further the fact that the results of clinical investigations 
antituberculosis drug bioavailability, done in healthy volunteers will differ from 
those similar are done patients. important in 
particular when outcomes are to be extrapolated or interpolated from 
volunteers to patients and versa. 
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Mean 
II 
SEM 
II 
• 
Test 2 
Mean 
SEM 
Test 1 
Test 2 
SEM 
Test 1 
Chapter 5 Correlation, Sub-Group and ...... "', ..... "', ... u Subject 
H 
5 
H 
13.45 
H 
38.62 
P 
6.19 
8.61 
1 . 
i 
, . 
. 
I 
I 
i 
, 
1 
, 
I 
J 
H 
21.77 
AUCT 
H 
55.43 
Aue 
98 
AUCI 
P H 
27.27 . 
AUel' 
P H 
30.01 75.78 
AueI 
H 
215.65 494.50 
3.91 
98 
P 
/ 
0.10 
P 
p 
422.65 
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Residual likelihood analysis 
support of the findings correlation and sub-group analysis as reflected in 
residual likelihood analysis (REML) was used to fit linear 
models to the logarithm differences of the pfllU1T:laCI)K11net:lC parameter 
pharmacokinetic AUCT of the 4 drugs mVlestl,gatled [36-38]. Based on 
ametelrs Cmax, were mvestlgatea parameter 
was to be better than vUU,LVU analysis. The basis with respect to 
(REML) analysis thus choosing AUCT for 
absorption and elimination of each of 
logarithm of the would therefore produce 
comparative using all 
............. 'LV-U-J model that was thus consisted of 
took into account a parameter, sex 
into consideration 
investigated. The 
nec:essary sensitivity to 
data set. 
cornp(ments. The fixed 
whether the subjects 
were healthy volunteers or patients, and whether the formulation used was 
.. ",t,~"""n("p individual drug(s) or test fixed-dose drug combination. The second 
was the random 
and 
Table 26. REML 
that mVlestljgatc~d 
"~U',Uv" [176]. 
onents 
vanous studies 
No of Stratum Variances Walden test for Fixed effect 
Units 
Study Units 
ts Patient 
496 10 5 247 O. 0.545 0.472 
578 12 286 <0.001 <0.001 0.338 
212 3 100 105 0.0 <0.001 0.188 
140 69 0.144 0.2 
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",VU,HJ.LJlU there was no effect due 
to sex. no was found whether the was a healthy volunteer 
or a patient; and no effect was confirmed by the formulation composition. For 
.. 'U..JJ.u.'-' confirmed that there was no due to formulation, but the 
sex of the 
had effect. 
whether the subject was a healthy volunteers or patient 
or female, and 
contributed an 
were mv'estl~ated 
effect was 
showed no effect due to 
subject was a 
"' ..... AI"" ... .,'"'. only the 
that were investigated were 
parameters of sex and formulation. 
5.4 SUbject Reduction analysis 
Subject reduction was mvestlga1tea to test for the minimum 
being male 
or oalClerlt subject, 
formulation 
in patients. No 
required for bioavailability bioequivalence testing. The VIJ"uU.JlU UllIIllULll11 time 
protocol as 
example, as it 
4 was employed, 13 as an 
bioavailability and bioequivalence results across all 
minimum time protocols investigated. 
A random process of aes:e!ectlrlg was used to eliminate subjects from original 
randomisation sequence to ensure that similar numbers remained in 
reference/test (RT) (TR) arms of the study reSl0eC11Vl:m 
subject numbers 18 is presented 
100 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Chapter 5 :on'elatloln. Sub-Group and "''''''''Y''',U Subject 101 
Table 27. Randomised deselecting of subjects 
Subjects 24 18 12 
1 1 2 
Rtf 2 2 7 
7 7 8 
8 8 21 
9 12 23 
11 14 24 
12 21 
14 23 
18 24 
21 
23 
24 
3 4 4 
4 5 10 
5 10 17 
6 15 19 
10 16 20 
13 17 22 
15 19 
16 20 
17 22 
19 
20 
22 
and 30 reDlres:ent the bioavailability 24, 18, and 
The present the Cmax, ,"'1.",-'11,"'", AUCT 
for reference test fonnulations. and standard error of the 
mean (SEM) were used. units of measurement for each of the 
are indicated in ora.CKc~tS: Tmax (h), (mg/l), Half-life (h), 
and (mg.hIl), The nl'lr,~rn,,·tnr Students-t-Test 1) and norl-D3lranletrlc 
Rank: test 2) were to detennine 
"ll".l11J.1\.,Ull' ... " between the and test fonnulations. Significance was 
declared where the p - obtained were less than 0,05 when .... vu.lJal the 
to the test. 
31, and 33 TPniT"''''''TlT the bioequivalence data 24, 18 and 12 subjects 
respectively, For bioequivalence testing the parameters of importance, 
AUC and AueI were summarised for each point with respect to 
difference nPT'""",,>" estimate, reference ratio, 
confidence and the most important parameter 
101 
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assessment, the 90% ""'v .......... "'. intervaL required data falls within 
confidence interval the data is presented in bold and when not within 
the required parameters it is presented as ordinary text. 
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Table 28. Biuav lilahility results of optimum !Jlu~u"'vl for 24 subjects 
Study 13 I~nnia7:icl (INH) 
N=24 Tmax (h) Cmax(mg{l) TI/2 (h) AVCT (mg.hli) AVCI(mg.M) 
HV R T R T R T R T R T 
Mean 1.19 1.30 4.66 3.14 17.12 17.01 22.88 21.33 
SEM 0.16 0.14 0.38 0.29 0.13 1.35 1.00 2.10 1.30 
Test 1 p= 0.50 p= 0.12 p= 0.17 p= 0.92 P= 0.30 
Test 2 P= .17 P= 0.67 P= 0.98 P= 0.38 
R:c~ . ~ (RIF) 
Tmax(h) r.. AVCT(mg.M) AVCI mg.M) 
R T R T R T R T R T 
Mean 2.08 2.25 I 11.74 10.75 3.69 4.00 50.58 46.07 70.08 68.17 
SEM 0.12 6 2.96 2.29 4.51 6.30 
Test 1 P V.l' .10 P 0.60 I p== 0.06 P 0.71 
Test 2 p= 0.24 p= 0.09 p= 0.22 I p= 0.07 p= 0.51 
Pyr"",;.,,.minp: (PZA) 
Tmax (h) Cmax(mg{l) TI/2 (h) AVCT(mg.M) AVCI mg.hIl) 
R T R T R T R T R T 
Mean ? 37.59 ... ,., on " ,.,'" 8.59 209.1 219.0 545.1 497.8 
SEM 1.47 1.42 0.65 0.55 8.63 7.69 36.67 30.00 
Test 1 0.77 P 0.09 p= 0.07 p= 0.16 
Test 2 P 0.34 p= 0.65 
Ethambutol (ETB) 
T 1'1 TII2 (h) Avcr n' 
R T R T R T R T I 
Mean 2.96 2.83 2.60 2.63 2.23 2.38 9.23 9.15 10.72 10.861 
SEM 0.20 0.16 0.22 0.21 0.12 0.12 0.7 0.95 0.95 
Test 1 p= 0.64 p= 0.88 p= 0.37 p= 0.92 I p= 0.90 
Test 2 p 0.81 P 0.93 P 0.27 P 0.74 
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TabJe 29. Bioavailahility results of optimum 1-'1 )1 for 18 subjects 
Study 13 Isoniazid (INH) 
N=18 Tmax (h) Cmax (mg/i) TI/2 (h) AUCT (mg.hIll AUCI (l11g.h11) 
HV R T R T R T R T R T 
Mean l.08 1.38 4.86 4.27 3.46 3.06 16.90 17.02 22.28 21.18 
SEM 0.17 0.16 0.48 0.36 0.38 0.15 l.65 1.25 2.51 1.65 
Test 1 p= 0.12 p= 0.13 p= 0.24 p= 0.93 p= 0.54 
Test 2 p= 0.10 p= 0.19 p= 0.72 p= 0.89 p= 0.69 
Rif~mnic,in J:RlFl 
Tmax(h) Cmax(mg/l) TI/2 (h) AUCT (mg.hIl) AUCI mg.hIl) 
R T R T R T R T R T 
Mean 2.11 2.31 12.05 lLlI 3.56 3.36 52.15 46.15 70.71 63.77 
SEM 0.14 0.18 0.77 0.62 O~2 i ::: ~ 5~8 5.48 
Test 1 p= 0.22 p= 0.12 0.13 
Test 2 p= 0.25 p= 0.13 p= 0.24 p= 0.05 p= 0.29 
Pyrazinamide (PZA) 
Tmax(h) Cmax (mg/I) TI/2 (h) AUCT (mg.hIl) AUCI mg.hll) 
R T R T R T R T R T 
Mean 2.53 1.89 38.19 38.90 10.04 8.59 214.7 223.4 565 511.0 
SEM 0.18 0.22 1.79 1.63 0.80 0.71 10.63 9.17 40.44 38.25 
Test 1 p= 0.58 p= 0.08 p= 0.22 p= 0.19 
Test 2 p= 0.62 p= 0.16 p= 0.11 p= 0.45 
Ethambutol (ETB) 
Tmax (h) Cmax(mg/l) TI/2 (h) AUCT(mg.hIl) Aucr :mg.hll) 
R T R T R T R T R T 
Mean 2.94 2.81 2.50 2.79 2.19 2.31 9.23 9.85 10.50 11.64 
SEM 0.26 0.13 0.27 0.27 0.15 0.12 0.94 0.97 1.08 1.16 
Test 1 p= 0.67 p= 0.33 p= 0.51 p= 0.58 p= 0.40 
Test 2 p= 0.91 p= 0.34 p= 0.36 p= 0.62 p= 0.54 
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TabJe 30. results of 
Study 13 Isoniazid 
N=12 Tmax 
HV R T R T R T R T R T 
Mean 1.10 1.50 4.62 4.00 3.09 2.91 15.78 16.65 20.23 20.39 
"-
SEM 0.21 0.20 0.45 0.36 0.36 0.18 1.22 1.58 2.03 2.03 
Test 1 p= 0.12 p= 0.25 p= 0.57 p= 0.54 p= 0.93 
Test 2 p= 0.10 p= 0.38 p= 0.97 p= 0.62 p= 0.97 
Tmax 
R T IR T R T R T R T 
Mean 
I 
2.21 2.42' 12.51 10.63 3.35 2.96 52.89 44.07 70.26 57.71 
SEM 0.16 0.23 0.96 0.66 0.14 0.22 4.80 3.42 7.13 5.76 
Test 1 p= 
Test 2 p= 
Tmax 
I 
R T :R T R T R T R T 
I 
Mean 2.50 2.04 39.29 38.98 9.16 7.14 215.8 223.0 529.8 447.9 
SEM 0.20 0.29 2.31 2.30 0.86 0.34 14.58 11.71 46.51 26.16 
Test 1 p= 0.85 p= 0.44 p= 0.05 
, 
Test 2 p= 0,91 p= 0.23 p= O.ll 
Ethambutol 
Tmax 
i 
R T IR T R T R T R T 
, 
Mean 3.04 2.75 2.42 2.74 2.22 2.41 8.78 9.58 9.92 11.41 
SEM 0.38 0.20 0.34 0.33 0.21 0.15 1.06 1.14 1.12 1.33 
Test 1 0.56 0.44 p= 0.50 p= 0.56 p= 0.37 
Test 2 p= 81 p= 0.52 p= 0.42 p= 0.57 p= 0.47 
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Study 13 
N=24 
HV 
Cmax 
AUC 
AUCI 
Cmax 
AUC 
AUCI 
Cmax 
AUC 
AUCI 
Cmax 
AUC 
AUCI 
Med.ian! Point 
Estimate 
1 
91 
91.86 
91.48 
100.21 
106.33 
94.81 
100.39 
91.79 
94.77 
Reference 
0.98 
razinamide 
1.02 
1.06 
0.96 
Ethambutol 
1.15 
1.11 
1.16 
106 
90% 
Confid.ence 
71. ....... - 13.82 
88.06-111.99 
85.51-100.82 
85.74-100.39 
1.66 
% Span 
22.76 
21.49 
23.93 
15.30 
12.13 
14.65 
14 
34.40 
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T bl 32 B' , 1 a e . lOeqUlva ence resu ts 0 f optImum protoco 1 D 18 b' t or su ec s 
Study 13 Medianl Point Testl 90% % Span 
N=18 Estimate Reference Confidence 
HV Ratio Interval 
Isoniazid (INH) 
Cmax 9l.58 0.96 80.67 -104.70 24.04 
AUC 105.08 l.11 89.31-118.20 28.90 
AUCI 99.33 1.07 87.21-114.11 26.90 
Rifampicin (RIF) 
Cmax 91.52 0.95 85.75-100.43 14.69 
AUC 89.52 0.91 83.25-95.55 12.30 , 
AUCI 88.53 0.92 83.26-95.19 11.94 
Pyrazinamide (PZA) 
Cmax 102.13 1.03 96.60-108.79 12.19 
AUC 106.33 1.06 100.94-110.13 9.19 
AUCI 91.50 0.94 80.01-105.76 25.75 
Etham butol (ETB) 
Cmax 110.53 1.27 89.72-138.34 48.61 
AUC 104.68 1.21 84.59-127.62 43.03 
AUCI 103.58 1.27 87.75-133.97 46.22 
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Table rotocol for 12 
Medianl Point 90% % Span 
Estimate Reference Confidence 
Cmax 
AUC 
AUCI 
AUCI 
AUC 
AUC 
AUCI 
89.90 
105.49 
101.07 
85.76 
85.67 
82.99 
99.94 
106.63 
86.39 
113.47 
105.00 
103.58 
P 
Ratio 
Isoniazid 
1.10 
1 
1.00 
1.06 
1 
1 
1 
all drugs, Cmax values fell within 
were included in the analysis. 
a reduced sample size was used 
Interval 
71.47-116.38 
90.18-126.13 
82.40-126.85 
80.21-95.11 
77.88-93.32 
76.85-88.61 
90.72-108.12 
98.96-111.05 
74.52-101.87 
84.52-156.22 
80.70-135.15 
81.53-148.63 
44.91 
14.90 
1 
11 
1 
12.08 
10 
therapeutic range whether 24, 18 and 
were not significantly rhH'Pt'pnt 
RIF. When 
was reduced to 12 subjects, of rifampcin were ;:)1l".j'UU'-'ULLU 
,1'\1"'I'1'(! were 11',-,'''''\.1\.'\.1 in the analysis. those when 24 
and AUCI parameters 
subjects were used, in the 
overall template that is fairly consistent 
were also significantly rhH'",,..,. ... + 
.. " ..... p:,<Uj'vu. This shows deviation 
and 18 subjects, respectively. 
108 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Chapter 5 
The results indicate 
and Reduced Subject Analysis 109 
potentially utilise 12 subjects, to investigate 
the bioavailability, _ ... ,,~~.,..., .. could anticipated relative to the current 
24 subjects testing protocol, in particular. On the side of caution in view 
of the current investigation it is evident that 18 subjects would be acceptable. 
pharmacokinetic parameters Cmax, For bioequivalence all the 
AUCT and Aucr fell within 90% "'V'LLI\.I''''''\_''' 'nT"' ..... 7O 24 subjects were 
included. Reducing the subject number to 18 as 
favourably and were within the '"'v ......... ,"'''\.''' .... T"" .... '" 
results compared 
PZA for 
was not the case for parameters Cmax, 
ethambutol whose COlUlQlenl;e .... T"' .... ", 
the subject to as 
complied with the necessary confidence ,n,,,·n.,,, 
pyrazinamide, Cmax and AUCT. The interval 
the upper end of the required range 
pharmacokinetic parameters were all outside 
parameters fell outside of the cpnfidence 'TlT"'''''''> 
pharmacokinetic 
parameters. 
following parameters 
rifampicin, only Cmax; for 
isoniazid fell marginally outside 
and AUCI. The other 
'"'Vll ......... .., .. ' .. '" interval, arid all 
ethambutol. 
number 
context 
optimum 
selected 
number of 
to 12 
clinical range 
and 
pharmacokinetic parameters were also not The 
was RIF that was within clinical range, but the showed the 
to be significantly different for the pharmacokinetic oarameters Cmax, 
and AUCI. 
109 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
5 """,,,, ... u,_,, ... Subject 110 
With respect to bioequivalence whilst 24 subjects and optimum 
minimum time protocol, all drugs all pharmacokinetic oarameters were 
within the intervaL For 18 only ethambutol was not within the 
confidence interval but the other drugs and PZA were within the 
confidence indicates, FDe's with 
combination investigated with 18 and the optimum 
time protocol of 2 (with sampling times at 0, 0.25, 0.5, 1.0, 1.5, 2, 2.5, 3.0, 
4.0, 6.0 and 8.0 hours) would be adequate. would be that 
would be marginally out with respect to AVe. 
parameters complied 
outside. 
ethambutol were not 
the confidence 'TIT"'."", 
interval values for 
the necessary limits. 
desired confidence interval in comparison to 
investigated. 
subjects some 
others were 
AVCT and 
on 
of 
overall picture does not yield 
of 24 and 18 
limiting analysis 
ptp'nYllnp the reduced 
I t:1:i,Dt:I"L to bioavailabiHty bioequivalence to 
number that would appropriate for UAI...,U.-U 
combinations, is in fact the bioequivalence analysis. The bioequivalence 
is of most relevance in evaluating the suitability of new formulations 
"' .... y, ... '"' • .., FDCs) to replace in established use the reference 
Therefore for combinations it 
would be the minimum, the overview as 
that 24 
"""\',L""'''''''' and the results 
obtained, three and two ofINH, RIF, and (excluding ETB), 
18 could be appropriate. 
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Chapter 6 
Conclusion 
111 
The objective of the study was to investigate a of modified screening-time 
OfOltOC:OlS used for bioavailability and bioequivalence studies anti-tuberculosis 
combination formulations to determine minimum time points 
that are required to confirm bioavailability and bioequivalence relative to an 
.... "Io.1,,, .. ,,'l". 15 time point protocol (0, 0.25, 0.5, 1.0, 1.5, 3.0, 4.0, 8.0, 
12.0, 24.0, 48.0 hours). 
The u"",,,,?'.u of all """",.."'" in this complied South African 
national drug regulatory authority requirements determination of 
bioavailability and bioequivalence testing of fixed-dose 
formulations. The fonowing parameters for bioavailability were compared using 
curves: Cmax, and For 
bioequivalence, the and were used. This data is 
presented Chapter 3 as the extended protocol results and was as 
the comparative to determine the optimum minimum time schedule. With 
exception of study 9 outcome of the 13 studies investigated, indicates that 
all the provide sufficient of bioavailability 
bioequivalence pharmacokinetic parameters and the relevant criteria as 
set out in Chapter The and conclusions from studies formed the 
basis for conclusions follow. 
In ChliDt(~r 4, obtained in ~nantf~r 3 using extended 1 point 
protocol, were compared to a modified minimum time protocol containing 
fewer points respect to bioavailability bioequivalence testing. 
comparative analysis on the pharmacokinetic parameters 
AUCT and investigated were also to confirm the optimum minimum 
time Eleven points, 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 8 
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were for demonstration of comparative bioavailability 
of INH, RIP, PZA A of 6 points, 
at 0, 1, 6 and 8 hours, is not sufficiently reliable for determining the 
bioavailability bioequivalence of anti-tuberculosis fixed-dose 
formulations. This is particularly relevant when Cmax and AUCr parameters were 
compared the and test formulations. 
In Chapter 5 the objective was to n .... ',.,."' .. ,,,, and investigate the number of 
dose drug as an data set, companson individual 
to combined formulations, sex, and disease status. 
When the data for all the studies was pooled, following was observed: for 
healthy volunteers and patients, sub-group analysis, compared individual drugs 
to combined formulations, that Cmax had significantly values 
the individual products than the test products, in rest)ect 
of and RIP, but not for PZA and There were no 
in AUCTor 
Cmax, and for INH, and PZA, respectively, showed " .. F> ........ "" ..... ~ 
TTPI'pn,r'po;:! between healthy volunteers and patients. volunteers attained 
Cmax for than patients. Patients attained higher 
for INH and than healthy volunteers. 
Bioavailability the tested anti-tuberculosis agents according to the 
study being investigated, clear differences were found oelwel:m 
healthy volunteers and patients. It is thus important not to assume 
outcomes will 
volunteers. 
achieved when doing studies in either patients or healthy 
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attained significantly Cmax and for RIF and 
when compared with males. It might thpf'pt,nf'P be important to 
treatment males and .l'-'U,lUHJil 
with were no differences 
he1:Wf!en females and males regard to the pharmacokinetic parameters 
and respectively. Residual maximum likelihood 
... v, ..... ." fitted for the AUCs, 
for conclusions. 
using linear 
supporting 
reduction analysis the optimum number of subjects required 
for bioavailability and bioequivalence assessment of a drug formulation. 
In for bioequivalence four-drug fixed-dose 
cornOlnatloDlS. more than 18 are required. 
to in a to determine the 
nXI~u-um;e drug combination would therefore need to 
A bioavailability and bioequivalence protocol 
nummum This reduces 
RIF, 
of striving 
quality of a 
uses optimum 
and cost, 
of the fixed-
points has been 
"V',"',,,,,, regulatory 
combinations investigated. modified protocol will not compromise 
and policy. 
The minimum time points schedule 
armlaCQlkln,etlc trial( s) tlmle-CC)flCe:ntnltl 
post-
about a potential 
measure of the quality of an 
surveillance. 
should be apparent 
that less sp~~cunerlS are "'-',,, ............ fqr 
for the FDCs. 
of time to determine outcome or 
FDC in the with respect to 
Whilst 
who predominant players, by already having 
companies 
in the 
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pharmaceutical 
114 
find the modified 
protocol attractive enough to engage process of producing with the 
rigors of authority requirements, thereby to the 
the manufacture of fixed-dose formulations. 
These can further contribute to the WHO and relevant 
information to support the FDC the Model of 
Drugs. the and time points schedule 
protocol as proposed, could become the policy of choice. 
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Appendix 1 
Information and Consent form example 
SlJBJECT INFORMATION AND CONSENT FORM 
130 
bioavailability and bioequivalence rifampicin, ethambutol, isoniazid and 
pyrazinamide as a dose in a dose combination formulation, compared 
to equivalent doses drug r",·E",,..,,,,·,,,.,.,,, of the drugs. 
Study dose combination tablet 
contammg rifampicin 150 mg, ethambutol mg, isoniazid 75 and 
pyrazinamide 400 has been developed recently by Novartis the treatment of 
patients tuberculosis. of in FDCs for 
has certain advantages drug distribution and administration. it is 
necessary to prove that the drugs reach blood concentrations in humans equivalent 
to achieved drugs known to be of good efficacy, quality. 
The aim of this study is to evaluate bioavailability of the new compared to 
that of equivalent single reference products, and to determine 
whether the new product is bioequivalent. 
design and performance. study will consist of 2 treatment periods of 48 
each. At treatment you will either the or the rpt,Oorpl11"P 
tablets. On each occasion you will take a total of 600 rifampicin, 1100 
mg of ethambutol, 300 of isoniazid 1500 or 1600 mg pyrazinamide. 
drug will by 1 week. 
Description of screening procedures (within 4 weeks before the study). Screening 
will place Department of Pharmacology (K Old Main ...... UllUll1!:), 
U"""" ....... Hospital) by prior Irene ......... , ....... 
Screening win include a physical examination, blood pressure and heart rate 
measurement, as well as routine blood unne screening recreational 
tests my and Pre-test counselling includes 
information the my virus / AIDS, way of spreading, risk factors and 
consequences will provided verbally by screening prior to test. 
For the individuals positive, follow-up will be made available at 
Schuur Hospital my clinic which includes access to both doctors and social 
workers. 
Approximately of blood be collected and a sample. 
You included in the study 
.. are a healthy volunteer, 
.. Your weight is the range by body mass indices. 
.. Your history, examination and laboratory values are normal, as 
assessed by clinical investigator. 
blood and rate are 
slglrlea informed consent to participate in the study. 
~"-=""'" be included in the study if the fonowing is recorded: 
illness or conditions considered by the medical doctor andlor described in 
protocol as a reason excluding you the (examples: high blood 
cancer, etc.). 
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• of hypersensitivity to a drug(s). 
.. Active allergic disease or a history of significant 
• History of drug or alcohol addiction. 
• Consumption of quantities of coffee, tea, alcohol wine. 
.. Blood donation of more than 500ml during the previous 6 months. 
.. Positive test for mv and hepatitis B. 
• a smoker or have smoked at in the 3 months prior to study. 
131 
.. any or medication (including the oral contraceptive) within 2 
weeks the study, or within a month of the study the case of 
medications. 
• pregnant or at of becoming pregnant. 
Description of each period. will be to to 
Pharmacology Department on before the drug dosing days at 
08hOO. 
are to meet at (on E Floor at of 
Groote Schuur Hospital at 20hOO on the evening each dosing day. You 
will admitted to ward G13 before receiving a supper. will 
overnight from and you will continue to fast until 10hOO following day 
when a standardised will be A standardised will 
served at 13hOO a standardised supper will be at 18hOO. Further 
will available after lunch. 
morning of the dosing a venous cannula will be into a suitable 
arm Through this cannula blood samples will be collected for first 12 
hours medication. 
~ ... t'n ..... TP"P"c/lTH. the first you will have the following procedures: 
.. Measurement of blood pressure, rate and tenlpe:rat1ure 
will receive treatments with water sitting in an upright position. You will 
remain in the sitting position for another 30 minutes and thereafter semi-
recumbent until 2 hours after each treatment. 
Blood sanlples be collected for drug 
medication, 0.25, 1, 1 2.5, 4, 6, 
administration. 
at following times, before 
24, 36and 48 hours after drug 
You will leave the after the hour blood sample, but will required to 
report to the Department of Pharmacology at following day the 
blood at for 36 sanlple at 07h55 on second 
drug administration for 48 hour sample. 
During the second treatment period, the above mentioned procedures be 
repeated. 
You be required to report to the Pharmacology Department at 08hOO for 
further blood 6 days after last administration. These are 
tests" to detect the unlikely event of damage to your liver, kidneys or blood after 
exposure to the study drugs. Not more than 340ml blood will withdrawn 
the study for drug and laboratory tests. 
Subject's obligation. Please follow the requirements listed below: 
.. YOU ARE TO CONSUME COMPLETELY THE MEALS 
PROVIDED. are only allowed to eat the standardised meals and 
refreshments provided, this is to limit individual variation in the absorption and 
metabolism of the study drugs. 
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II You are not allowed to take any non trial medication, including over-the-
counter remedies throughout study and in the before study 
without consulting the investigator in advance. 
• No strenuous physical activity be performed 48 hours before 
until 48 hours after each administration. 
.. No alcohol or caffeine may consumed before until 48 
hours after administration. 
Withdrawal from study. It is the any to withdraw the 
study. Subjects must agree to obey instructions of the investigator concerning 
matters pertaining to the health of the individual after 
clinical investigator may withdraw subjects from clinical reasons or 
protocol violations by the subject. Protocol violation is defined as wilful 
"uU'''''.U'''U~J''' of instructions communicated or writing. 
Subject remuneration. Compensation time-loss and inconvenience suffered as a 
of in the will on completion the 
Subjects who do not complete the study bona fide reasons or other clinical 
considerations will be compensated according to amount of time lost and 
inconvenience i.e. on a_pro rata basis. Protocol violation may result in 
of remuneration. 
Information on adverse events. Please report any unusual symptoms or 
deterioration in your health to the investigators immediately. The treatment 
which will be taking been with the following adverse events: 
adverse events: of appetite, vomiting, abdominal discomfort, rashes, 
pains headache are relatively common (l1l0 to 11100). Uncommon 
effects include hepatitis (liver damage), peripheral neuritis, "flu-like syndrome", 
hypersensitivity, blood dyscrasias (damage to the blood cells), nephrotoxicity 
(kidney damage), neurotoxicity and optic neuritis. Rifampicin may produce an 
orange-red discolouration body fluids; contact lenses should not be worn until 
hours each administration. 
Subject's information. Participation in this study is entirely voluntary, you are not 
obliged to part. you decide to part you will to to say 
you gIven consent to participate. If you to participate, you may 
withdraw from study at any time, without prejudice to you doing so. 
personal information obtained about you the course of this study will remain 
confidential and in reporting results of the study, you be to only by 
a number. 
In accordance with legal requirement, during the course of this clinical you 
will be covered by an insurance policy. 
You will be a copy of this information sheet and consent form, and may 
the following contact persons for additional information, at time during the 
132 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Appendices 133 
021-406 
to take part the trial of the bioavailability of a fixed dose combination 
tablet containing rifampicin, ethambutol, isoniazid and pyrazinamide. 
I confirm that the Supervising Doctor, 
_______________ has me a full explanation 
the nature, purpose and duration of the study and I shall be expected to 
do and has advised me about the ill-effects, including discomfort or 
inconvenience, to health or well-being believes from 
participation. I have also read an information document 
3. I have been informed an insurance policy has been taken out for this 
4. I the opportunity any questions concerning the study 
satisfaction understood the doctor's explanation 
and advice. 
5. I have informed the supervising doctor of all my previous or present illnesses, 
together with any medication/drugs, of whatever nature, I have taken in the 
month, or am taking, or am planning to take, whether prescribed or not, and 
consultation that I have had with my doctor in the last months, whether or 
not it resulted in medication or drug therapy. 
6. I have further informed the supervising doctor of any participation by me in 
other volunteer the past 
7. I confirm that I do not fulfil any of exclusion criteria this study as 
described in volunteer information document. 
S. I to comply in good faith with instructions to me by the 
doctor undertake to him once if I any 
unexpected and symptoms or any deterioration whatsoever in my 
health or well-being however .... a.u,;:,'Vu. 
I am aware that this study been to review by an Ethics 
to undergo blood tests as described the subject information 
document, including a test for AIDS virus. 
I understand that the following carried as part 
study: 
a) Administration of the study drugs on 2 occasions. 
b) withdrawal of blood during the periods as described in 
the subject information document. 
11. I understand that I am free to withdraw my consent to participate in study 
at any without need to my but I confirm that while 
participating in the study I will not knowingly anything that I 
reasonably assume could the of it. I further understand that any 
becomes available course the that may 
affect willingness to take part will be disclosed to me as soon as practicable. 
On the that my name in connection with this study will not be to 
any person other than Sponsor or Regulatory Authority, I do not claim to 
be entitled to restrict in any way the use to which results study 
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be put. particular, I to disclosure of any report of those results to 
Regulatory Authorities for medicines. 
13. I that representatives the Company or Regulatory 
may wish to my medical to the information collected. By 
signing this document I permission for this review of my records. 
I am aware that, although this study may help the of meOlCaI 
knowledge, I will not directly receive health benefits from it, and that if I have 
not been truthful in any of the information I have or if I do not fully 
comply with directions given to me, I harm myself by participating in 
the 
I confirm that I have received a copy Consent Form and the Volunteer 
Information to the 
Last Name 
.... .1 ..... .1 ...... . 
Signature of volunteer 
PlacelDate ... . . . . . . . . . . . . . . . . . . . . . . . .... .I. ..... ./. ..... 
I confirm that I have explained nature, purpose and effects of the 
trial to the volunteer whose name is printed above, and that he has consented to 
participate. 
The volunteer "nr.h .... """"rI consent signing above. 
of supervising doctor 
Date ..... .. . .. I. ..... 
(please print) 
Signature of supervising doctor 
134 
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Data files 
135 
Attached are data files of the 13 reSlJec1tlve studies can be opened in 
WinNonlin Standard Edition Version 1.5 (WinNonlin © 1984-1997, Scientific 
Consulting, Inc) or Microsoft ® 97 (Excel © 1985-1997 Microsoft 
Corporation) using the comma delimiter function to get access to the data. 
The are named as follows in order respective studies with 
extention . 
. dat 
Study2.dat 
Study3.dat 
Study4.dat 
StudyS.dat 
Study6.dat 
Study7.dat 
Study8.dat 
Study9.dat 
StudylO.dat 
Studyl1.dat 
Study12.dat 
3.dat 
UNIVERSITY OF' CAPE TOWN 
UNIVERSITEIT VAN KAAPSTAD 
135 
file 
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Appendix 3 
Pharmacokinetic profile 
A selected pharmacokinetic profile as determined 
curve plots indicating subject number in study, drugs ....... o'~"'n. 
combination ... ""+" .... ",, ... ,,",0 graphs resc,eCtlvelv 
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Appendix 4 
ated 
Referenceff est 
1,2, 4,5,6,7,8,9,10,11, 12, 14,15, 16 
6, 8,9, 15 
1, 3, 4, 10, 13, 14, 16 
3,5, 7,10, 14, 17,18,23,24 
2,4,8,9,11, 13, 15, 19,20,21,22 
1, 3, 9, 19, 20, 
2, 7, 10, 11, 13, 14, 15, 16, 21 
2,3,4,5,6,7,8,9,10,11, 
13, 14, 15, 16, 18, 19, 20, 21, 
1,4,8, 9, 10, 12, 13, 16, 18 
21,22 
1,3, 6, 10, 11, 18, 19,20, 21,22, 
14,15,16,17,23 
1, 20, 24 
3,4, 9, 10, 12, 16, 17, 18,21, 
2,3, 6,9, 14, 16,17, 19 
1,4,7,8,10, 
! Study 9 3,4, 6, 10, 12, 13, 14, 16, 19,21, 22 
137 
~ 17,18,20,23, ~t-U-d-y-I-0----4-~----~2~,~4-,9~,-I~I~,~1-2~,1-4-,~~1-6'~1-9-,~2-2~,-23------~ 
1,3, 5, 6, 8, 10, 13, 17, 
Study 11 2, 5, 8, 10, 13, 17,18,21,23 
4 ,6, 7, 9, 11, 12, 16, 19,20,22,24 
Study 12 1, 4, 5, 8, 10, 14, 18,21 
6, 7, 9, 11, 16,19,20, 
Study 1, 7,8,9,11, 12, 18, 21, 23, 24 
3,4, 15, 16, 17, 19, 
137 
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Publications 
McIlleron, H., Gabriels, G., Smith, P. , 
development of a standardised screening protocol 
rifampicin bioavailability Int. 1. Tuberc 
138 
(1999) The 
G., Fourie, P.B., Padayatchi, Onyebujoh, McIlleron, Smith, P., 
Gabriels, G. (1999). Recent bioequivalence studies on fixed-dose combination 
anti-tuberculosis formulations on the global market. Int. J. Tuberc 
Lung Dis, 3(11): 16. 
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INT J WHERe:: LUNG DIS 3(11):5329-5335 
@ 1999 IUATLD 
The development of a standardised screening protocol 
for in vivo assessment of rifampicin bioavailability 
H. Mcllleron,'" G. Gabriels,'" P. J. Smith.'" P. B. fourie,t G. A. Ellard* 
,. Department of Pharmacology. University of 
Programme, Medical Research Coundl. Pretoria, 
Town Medical School. Observatory. tTuberculosis Research 
Africa. * Department of Medical Mjcrobio(ogy, 
St George's Hospital Medical London, UK 
_______________________________ ~-s U M MARY 
SETTING: The for in vivo bioavailability 
of rifampicin in fixed-dose combination 
. formulations is widely accepted. However, many smaller 
drug authorities drug malnUlac:au'ers 
have difficulty imItIentenll:ing 
testing procedures. 
OBJECTIVE: To test wl1letller 
schedule can be used for 
bioequivalence in dose. crossover 
studies of FDCs and appropriate reference formuilations. 
METHOD: The results of three bioavailability and 
bio,eqllliv;aleJllce studies different rifampicin-containing 
FDCs were analysed. relationship the num-
ber time points employed and of estimated 
rel;ati~re bioavailability was explored. The relative bie-
availabilities the drug in the test FDCs 
THE NEED TO "rI,",,,,,,,,1' .. bioavailabil-
ity of rifampicin in fixed-dose combinations 
has long recognised. highlighted the 
detnOiustratmg the quality of U~';""IJ'­
annual mt~etJlng 
.. u ..... "'" •• ,,"', .. ,, .. Union £"/5,"".''''' 
Disease (IUATLD) in Dubrovnik in 1988. In a 
symposium entitled 'The quality of antituberculo-
sis drugs' he presented the findings of an investiga-
. bioavailability formulations con..; 
rifamJ?icin 
1-1'I,·pp.t1r',1(T FDCs containing uu;u .. l" ...... ,,$ 
pYI"azinalnid.e, He denlonstra,ted 
clinicaJ use,l 
were concentration and area 
under curve estimates based on an extended blood 
sampling schedule of up to 15 time over 48 UVULA.,.. 
a sampling scheme with only six blood 
samples over 8 hours. 
RES U L T s: Estimates of relative bioavailability calculated 
using the contracted blood sampling protocol were 
CONCLUSION: 
efits can be 
to those derived using extended sam-
schedule with a ~ the of 
the estimation of relative rifampicln bioavailability. 
KEY fixed-dose combination; bio-
availability 
Corre~pondenceto: Dr Helen McIlleron, Department of Pharmacology, of Cape Town Medical Obser-
vatory, South Africa Tel: 21 406 6286. Fax: 21 448 1989. e-maH: hmciller@uctgshLuct.ac.za 
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Table 1 Dates and drug for each of the studies 
1 : test formulation 1 
2: test formulation 2 
3: test formulation 3 
10/1996 
10/1997 
0211998 
the treatment to patients. It follows an "' .......... ," .. 
and standardised is needed to test 
anFDC 
grammes. 
In vivo demonstration of adequate absorption 
FDCs is important for In 
addition to the of bioavailabiHty 
resulting from variations in particle size, 
excipients and manufacturing pr.c)Cf:8S. 
, drug has low in water and hence poterlt1~ll 
absorption problems, is subject to enlterc)hc:pa.tlC 
circulation, Il which complicate 
Organization (WHO) 
are in a collaborative UULlaLl 
assist small National Drug Regulatory fl.U,UH.n 
to ensure acceptable standards of quality, 
etb:ca(:y of FDCs or manufactured 
jurisdiction, m(:lUclm:g 
basis for assuring HU<;;L",U"U~''''''''U'LT 
Simultaneous this 
venture, the of Pharmacology at the 
University of (UCT), South Africa, 
conducting a 1HU."V'., of bioavailabiHty ;>L\JlUU;;> 
FDCs since 1996, . for registration 
poses, and according to guidelines issued by 
WHO.9 
of 
containing FDCs, Department of 
has collaborated with the WHO. Analysis 
studies of three provided evidence that 
a contracted and more protocol can 
unt'hn':1i" '''~UJ'U'''~''''',Ll c1om,pr()miSlflg the pre:C1Sllon 
Dosage of test formulations and the reference agents 
600 . 
600 
600 
300 
300 
250 
1500 
1500 
1500 
1125 
1000 
o 
METHODS 
StllLQ1c~S analysed were selected from 
... v ...... 'u .... ,.:;... in the department since September 
would provide data ort 
estimating relative bioavailabilities of three, of 
key antituberculosis drugs, and of the previ-
ous evidence1 that manufacturing with ac(:et:~1:-
able bioavailability was to be most 
were included. 
form and were 
fully bioavailable bioequivalent to 
reference agents. Formulations 1 and 
develope& and the .:>~uu. ... ;:"" 
were for registration purposes. Formula-
tion 3 was a generic formulation manufactured in 
Malta for International Ul:spe:ns:u 
Two 
For test 1 each contained rifampi-
cin 120 mg, isoniazid 60 mg, pyrazinamide 300 mg, 
and ethambutol 225 mg; for test formulation 2 each 
tablet rifampicin 120 isoniazid 60 
pyrazinamide 300 and ......... uu .... , .. 
third FDC 3) was a com-
"'VJliL""UJ'H~ rifampicin 120 isoniazid 50 
........ u" ............. 300 mg per total 
study are 1. 
was used study, in 
was r_andomised to receive a single 
test formulation or reference 
administration (Unpublished 
[1996Jand [1997] 
Tw·pntv-rwn to 24 
het'wef~n 18 
Table 2 Peak rifampicin plasma concentrations «(ma,,), time to reach Cmax and AUCt for the three studies. For studies 1 and 2 the 
area under the curve was calculated to 24 hours, while that for 3 was calculated to 12 hours. Standard errors are dislpla~(ed 
in parentheses. 
13.0 (0.9) 
10.1 (0.6) 
12,2 (0.8) 
2,2 (0.1) 
2.2 (0,1) 
1.6 (0,2) 
1T(0.1) 
2.3 (O.l) 
2.0 (0.1) 
70.7 (4.7) 
60.5 (3,5) 
64.3 (5.4) 
65.7 (3.3) 
58.2 (2.5) 
64.9 (4.8) 
62,4 (3.7) 
52.4 (3.0) 
64.3 (5.4) 
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Assessment of 
Table 3 Peak isoniazid plasma concentrations 
expressed in parentheses. 
time to reach (fma,J and AUC0-24 for two studies. Standard errors are 
No. of Test 
to ensure that 20 completed each study). ~mlol<:ers 
volunteers a history of or alcohol 
were excluded, as were those a history of'drug 
allergy, severe asthma or active or recurrent allergic 
disease. No volunteer treated tubercu-
losis or liver ..... "',, ... ,,". 
intestinal disorder was included .................. , ...... F.o 
liver and function and hae-
.. v .... , ..... Written informed 
each prior to 
sumption strenuous exercise 
and after drug No 
that might alter or elnnulatllon 
permitted in the month prior to study L<"' ...... ,"""". or 
during the 
. TheFDC 
3 
to 
formulations 1, 2 and 
were compared 
and rell:istered ''',U!<.lC·'.u 
The of 
was 600 mg, and doses of isoniazid, pyrazinamide 
ethambutol were also in keeping with 
range adults W<';:l!;ll1l1!; 
or more.ll drugs were ..... uLlln .. ' ...... 
~ dose 200 ml of water, 
one between drug administrations. 
Subjects fasted for 8 hours drug aarmn:lstt:a-
Table 4 Estimates of relative isoniazid bioavailability 
of formulation 2 (as by the 
of Hauschke et al. 17 
Cmax contracted 110.5 98.0-125.2 27.2 
Cmax full data 101.5 90.0-111.6 21.6 
AUCo-a contracted 101.5 94.7-110.5 15.9 
AUCo-a all data 97.0 89.1-105.1 16.0 
AUCI)-.12 all data 98.0 9Q.9-106.7 15.8 
AUCI)-.24 all data 100.1 91.4-113.9 22.5 
Test 
1.2 (O.l) 
1.1 (0.2) 
20.2 (1.4) 
22.8 (1.9) 
drug administration a 
18.5 (1 
23.4 (2.1 
nn'lVIOf>.,. Five' hours toILIO'WlI:1Q' 
drug free intake was permitted. 
Adverse events were monitored clinically and 
lowed to resolution. If withdrawal a "'U'J"L"'~~ ................. '";; 
the drug administration 
ject was not reJ;'Ja(;ea and the pharmacokinetic data 
following the drug administration were eXlCJuaea 
the 
Venous blood were by vene-
puncture high performance liquid chromatography 
(HPLC) analysis of drug concentrations. Blood .sam-
were collected into two llttuum-nelpar 
ppJCO:Xlmately 0.5 prior to drug 
at ~,1.5, 3, 4,6; 
. 8,12, 24, 36 and 48 hours after drug administration 
studies 1 and 2., The were analysed 
ethambutol 
a maximum.of 
Table 5 Estimates of relative ethambutol bloavailabiJity 
of formulation 1 (as by the 
of Hauschke et al,17 
contracted 87.4 68.9-110.5 41.6 
full data 97.1 84.3-114.7 30.4 
contracted 109.0 86.1-1 50.4 
all data 114.7 94.2-1 40.3 
all data .110.5 94.4-133.2 38.8 
all data 109.7 92.5-138.8 46.3 
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. Table 6 Estimates of rifampicin bioavailability of 
test formulation 1 (as percentages) by the procedure 
of Hauschke et al. 17 . 
89.5 
104.2 
99.8 
103.4 
106.3 
106.1 
81.3-100.3 
95.3-114.1 
93.3-107.4 
96.8-111.4 
100.0-114,9 
99.0-114,3 
19.0 
18.8 
14.1 
14.6 
14.9 
15.3 
trations· 
HPLC 
were determined by 
a modification of liquid chroma~ 
LV6"''''J:'UI (GLe) method Wang,14 with a 
detection limit p,g/ml. 
Concentration-time curves were plotted each 
of drug using both the full set of sampling 
times (as above) and a set of sam-
pling the ' determined at 1, 
. 2,4,6 8 hours only were For each concentra-
tion-time curve, maximum drug concentration 
was as the level measured, and the 
. areas curve (AUe)O-lh AUCO-12, AUCo.-24 
(or AUC0.-4s areas 
under the curve to 8, 12, 24 or 48 respectively, 
... 'U .... Wl .... ~;U using the trapezoidal rule. AUCo-s was 
Cal(::uIa,tea using the data all the sampling times 
hPl'W'Pf'n 0 and 8 hours, using the COllceIltra 
det:enrulled at 0, 1, 2, 8 hours 
Bioequivalence of Cm"", AUCO-12 
and AUC0-24 (or AUC0-48 for pyr~zinamide), and Cmax 
and AUCo-s were conducted the full and con-
tracted sets sampling times The 
method described 
delterlDUle the 90% interval (90% 
test/reference ratio for each set 
bioequivalence the 90% CI should 
range 80-125%. 
pharmacokinetic of rifampicin, iso.: 
niazid, pyrazinamide ethambutol for 
those measur~tof principle interest are shown in 
1'_--
'~! 
Table 1 Estimates of relative ribmn,irin bioavailability of 
test formulation 2 (as procedure 
of Hauschke et al. l1 
Cmax contracted 103.5 93.7-118.8 25.1 
Cmax full data 101.8 92.9-119.1 26.2 
AUC;o-a contracted 110.2 101.2-125.0 23:8 
AUCo-a all 116.5 105.6-130.1 24.5 
AUCo-12 all 109.8 101.4-122.9 '21.5 
AUCo-24 all data 108.3 100.4-120.5 20.' 
Table 8 Estimates of relative rifampicin bloavailability of 
test formulation 3 percentages) by the 
of Hauschke et al. 17 
contracted 
full data 
contracted 
all data 
all data 
" 
Median/point 90% confidence 
104.5 
100.5 
100.7 
102.2 
101.2 
90.7-119.8 
89.2-115,2 
91.5-113.8 
91.7-115.5 
91.9-112.4 
29.1 
26.0 
22.3 
23.8 
20.5 
Tables 2, 3,12 and 10, respectively. Detectable amounts 
rifampicin,' pyrazinamide or ethambut:ol 
were not found any of the samples. By 
24 hours . concentrations had fallen to below 
detectable limits. Rifampicin was rapidly 
test the results that 
blOava,l1altJili1tv is likely to be excellent (Table . 
analyses for rifampicin are . 
7 and 8. The similarity between 
AUC to 12 and that to 24 
can be attributed· to . negligible L."t-nCHIr 
rit,amlpi(:in levels. More 'estimates of ........ "U.LV .. 
bioavailability were vv"aUlCU 
pared with '-'~.~v-Ui:l:>cu 
AUCO-ss ........... UJ, ........ 
120 
115 
110 
105 
100 
95 
90 
85 
80 
1 2 
J 
,---" ...• 
. 
J 
3 
90% confidence intervals of the test/reference ratio of 
calculated using contracted sampling times for each 
studies. 
.. 
~ 
f· 
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Table 9 . Estimates of relative isoniazid DIOi3VBlila 
of formulation 1 (as percentages) by.the 
Hauschke et al. 17 for study 1. 
Median/point 90% confidence 
contracted . 97.2 88.9-112.5 
full data 92.9 80.1-104.9 
contracted 110.6 101.3-120.2 
all data 
data 
data 
107.3 100.3-116.9 
110.1 104.0-117.4 
113.9 107.6-122.2 
which were essentially 
also demonstrate 
the spans of the 90% 
suggests that this was 
variability in the handling of 
voJiunteers rather than (l1tjten;:ncl~s 
pr1eCl:SlOfi between the studies. 
ISClru,3Z1.d showed rapid and excellent 
23.6 
24.8 
18.9 
16.6 
13.4 
14.6 
as demonstrated in Table 3. Considerably more pre- . 
cise estimates of relative bioavailability were ::1£"1111"1"1"<1 
than CriIlUl:S (Tables 4 and 9). 
ClernOllstl'ateCi in Tables 5, 10 and 11, "'~u, .. u ....... -
to1 in both test forniulations was excellently absorbed, 
although spans were observed for 
bioavailability confidence intervals, 
more 
re~;nJjteCi in only gains in the 1-' .. '; ... "", .... 11 
.... I"rt", .. bioavailability estimates 
was also rapidly and 
The 90% CI AUCo-s 
'"'VJLAu ...... " ...... ,,,,,,,nnl,na schedule correlated well 
.............. "U'l; ..... from all data; and 
culated from the contracted sampling times is 
similar to that obtained using the expanded schedule 
(Tables and 14). Although the AuCs 
the <=max values, the 
tight of the rapid absorptipn 
which is both highly water soluble and pene-
membranes extremely efficiently), even 
<;lata. the chance of thcif breaching the 80-
90% range is most unlikely. 
..... .,<U"':Il\..'" of all 
Assessment of 
Table 11 Estimates of relative ethambutol bioavailability 
of formulation 2 (as by the procedure of 
Hauschke et al. 17 
Parameter 
contracted 110.5 98.0-125.2 27.2. 
full data 101.5 90.0-111.6 21.6 
contracted 101.5 94.7-110.5 15.9 
all data 97.0 89.1-105.1 16.0 
all data 98.0 90.9-106.7 15.& 
all data 100.1 91.4-113.9 22.S 
obviates the need for' hospitalisation of subjects, 
requires considerably as a conse-
quence is considerably methods used 
previously. 
DISCUSSION 
It is currently recommended that bioavailability 
of rifampicin in fixed-dose co:mc~mlU1()nS demon-
to compare fa'IJ'ouxal,ly 
single-drug reference "'~'."J""""'.""'''''' 
prior to registration or h(;c~IiSmg 
ities. The 90% confidence 'nt· ..... ',,, 
of suitable 
of rifampicin in HA<;;U'-""""''';; .... VlIUIJUA ....... 'U<> <>U\.II..Il'U 
beltw~~en 80% In 
4 ..... ' ........ \.1 ... it may dem~ 
onstration of the continuing bioavailabillty of rifampi-
cin in the assessment of the quality of further batches 
of licensed FDC formulations, if 
re'ason to suspect that an p"I/',-, .... i ..... t-
process might have been ....... " .. 150."" •• 
Simplification of' registration 
minimum standards for licensing 
assurance for FDCs, is desirable, as 
advantages over the . 
formulations. A more 
retains the precision of more eXlteo,CleCi pro(:e.dur~:s 
should 
regulation of LlJ..:Ullp .... lH·· .... V.lll.~Llllll110 
analysis of the 
~upports.the use 
~::Itnnhnuschemefor ClemC)nstt~ltl 
rifampicin in FDC 
Proving bioequivalence of .!'I;!!.ll11':lLl''-', etharrrt5'Utol 
/ 
1 
2 
24 
23 
3.3 (0.2) 3.4 (0.2) 2.7 (0.1) 2.6 (0.1) 
2.9 (0.1) 
13.6 (0.7) 
15.8 (1.4) 
13.1 (1.0) 
14.9 (0.8) 3.7 (0.3) 3.5(0.2). 2.8 (0.2) 
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concentrations (CmaJ, time to reach erma.) 
<::t",nn.:>.n errors are shown in parentheses. 
33.8 (0.9) 
42.5 (2.6) 
isoniazid, 
COlnCf~ntJtat:lon:s, as was 
in this was a modest 
increase in costs over that for estimating rifampicin 
alone. bioequivalence confidence interval 
sis that in vivo bioavaii<ibility 
niazid, pyrazinamide and ethambutol can 
the contracted sampling schedule to 8 hours 
"rin<l'''''' excretion rifampi-
cin and represents another 
in which rifampicin bioavaiIability assessment 
be simplified,. an which is currently being 
authors_ 
me:th()(1s described in 
....... ,'''' .... vu averages 
reIlerelnce nrtvl"'l"t"" thus address-
ing question . Broadly, con-
cept of bioequivalence also encompasses aspects 
Table 13 Estimates of relative pyrazinamide bioavailability of 
formulation 1 (as percentages) by the procedure of Hauschke 
etalY . 
contracted 
full data 
contracted 
all data 
all data 
100.4 
95.9 
102.0 
99.8 
105.8 
Table 14 Estimates of relative 
of formulation 2 (as n"r'('''rlt'''(,,,~) 
Hauschke et al. 17 
Cmax contracted 102.0 
em .. full data 104.1 
AUCo-s contracted 99.5 
AUCo-s all data 98.0 
AUCo-12 all data 98.0 
AUC(}.42 aU data 99.0 
97.3-104.0 
103.1-10B.6 
98.5-105.1 
100.5-111.1 
96.6-102.5 
94.7-101.5 
95.1-101.5 
95.6-103.1 
11.6 
9.1 
B.6 
6.7 
5.5 
6.6 
10.6 
6.0 
6.9 
6.4 
7.5 
for 'switchability', 
a topic that is not 
guidelines on methods 
to 
"'UUU',<l.L" any 
CONCLUSION 
A of analysis 
for applied to both the extended and 
the contracted sampling tilpes indicates that little 
is gained the application of a more extended 
"""rlnl'na "' .......... , ...... , and that fewer times can 
be significantly compromising the pred': 
sian of rifampicin bioavailability estimations. Although 
the three studies analysed were from a single 
centre on a basis, results 
str(mglly ",.nn,nrt" the use of theWHOIIUATLD- . 
rec:onufliemleCl protocol rifampicin 
bioequivalence of FDCs,10,18 The use method, in 
which only six blood samples are required up to 8 
hours drug administration, is considerably more 
corlvelrueIlt and and will hopefully lead to, 
quality of "' .. , ...... 1.1'.-. 
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Recent bioequivalen studies on fixed-dose combination 
anti-tuberculosis drug formulations available on the 
global market . 
G. Pillai,*t P. B. Fourie,t N. Padayatchi,t* P. C. Onyebujoh,t H, Mcilieron,§ P. J. Smith,S G. Gabriels,! 
it Department of Pharmacology, University of Durban Westville. Durban, t National Tuberculosis Research Programme. 
Medical Research Council. Pretoria, a King George V Hospital, P 0 Dormeton, Dormeton, I Department of Pharmacology, 
Medical School. University of Town, Town, South Africa 
SETTING: Concern has been about the- bio-
availability of rifampicin in some combina-
tion (FDe) anti-tuberculosis formulations. 
OBJECTIVE: To evaluate the relative bioavailnbility of 
rifampicin in various FDC formuI:uions currently in use 
in tubercUlosis control programmes in the global.market •. 
DESiGN: A two-period r:mdomisedcrossover bioequiv-
alenee study in healthy male volunteers, with It .. ~ week 
washout period between treatments. Plasma rif~mpidn 
concentrations were measured at 0, 1,2,4.6.'8' and 12 
hours·after each drug admjnj~tr3tion. ' 
r,'. .' ',-
IN THE TREATMENT 9fruberculosis, drugsformu-
bred In fixed-dose combinations might hold several 
advantages over' administration. of the individual 
drugs separately_ These include the following: r-4 pre-
scribing is simpler; prescribing errors are 
minimised; patients are less likely to be 
about numbers of tablets and capsules to . in 
self administered dosage schedules; drug doses .can be 
more precisely adjusted to the patient's weight; and 
the nllmber of pills to be swallowed is reduced. 
The main advantage, however, is a public health 
isslie. Since the drugs arc taken in cornbin:niull, the 
possibiliry of patients only taki g a single drug is pre-
vented and hence the risk of failure during treatment. 
as n result the selection 
gready reduced. This is 
don of rifampicin and isoniazid-the important 
'resistance preventing in the tuberculosis 
tre:nment regimen. 
However, concern has about 
apparent inadequate bio:lVai!abilit). of rif:ulIpicin in 
some fixed-dose combination (FDe) preparations/· .. H 
Consequently, intern.uional regulatory authorities 
recommend that the bio:wailabiliry of formuhuions 
be with that of preparations of reputable 
efficacy. Only those shown to be bioequivalent should 
be released omo market?" 
UMMA RY 
RESULTS:. The AUCo-s. AUCo-12 and for rifampi-
dn in seven of 10 FDC formulations was not found to be 
bioe'luivalent to the reference administered as loose 
(separate) formulations. This was confirmed using p;:ua-
metric :md non-parametric statistical methods. 
CONClUSIONS: The; poor relative bioavailabiliry of 
rifampicin from some FDCs has been documented. The 
implkations for tuberculosis programmes are extremely 
serious and warrant uf8~nt attention. 
KEY WORDS: bioavail:tbility; fixed-dose combination; 
rifampicin; tuberculosis 
This paper represents part of a comprehensi '\fe 
project in which the quality of FOC prep:.1nnions cur-
rently in use in various TB control programmes in the 
glob:!1 will be \VIe report here On the 
rifampicin .bioavailabiliry from 10 FOCs: three con-
tainingrifarnpidn and only (two-drug com-
binations), five conrainingrifampicin, isoniazid and 
pyrnzinnmide (three-drug combinations) nod [\Vo 
contnining rifnmpicin, isoninzid, pyrazin::tmide and 
ethnmblltol (four-drug combi{lnrions). 
METHODS 
Acquisition of study medications 
The FDCs under invesrigncion (Tnble 1) were sourced 
in terms of the market represemation of the m~mllf:tc­
rurers. 1O of the World Health Organi-
z.ation (WHO) nnd the lnrernational Union Against 
and Lung Disease (IUATLO) purch.lsed 
the medications from wholesnle/remil outler!: mrlll.·r 
than from the m:ll1uf:lcturer. TIlese were supplit:d tu 
South African Medical Research Council (MRC). 
where they were repackaged into :1inigln phlStic 
tubes, coded and labelled \\lith the content of active 
o;; ..... o;;'n:.. Repackaging was necessary in order ro 
ensure that clinical investigators were blinded 
to the identity (brand name) or country of 
Correspondence to: Dr G Pillai, Department of Ph:umacol0ItY, University of Durban Wesrville, Priv:lte Bag X5400 I, Dur-
ban, 4000, SOllth Africa. Tel: (+ 29) 31 204 4908. Fax: (+29) 31 204 4907. e-n13il: cpilbi@pixie.udw.ac.za 
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Table 1 Anti-tuberculosis fixed-dose combination (FOC) formulations investigation 
and reference formulations used in the 
fOC formulatio,)s Generic 
Formulation N Rifampicin 
Isoniazid 
Pyrazinamide 
Formulation C RifampiCin 
Isoniazid 
Pyrazinamide 
Formulation E Rifampicin 
Isoniazid 
pYrazinamide 
Ethambutol 
Formulation H Rifampicin 
Isoniazid 
pYrazinamide 
Ethambutol 
Formulation P Rifampicin 
ISoniazid 
Formulation 0 Rifampicin 
Ist;lOiazid· 
Formulation j Rifampicin' 
Isoniazid 
Pyraziryamide 
Formulation M Rif'lrtll{icin 
Isoniazid 
Pyraiinilimide . 
Formulation Q Rifampicin 
Isoniazid 
Formulation F Rifampjcin 
Isoniazid 
Reference formulations' 
Pyrazinamide 
600mg Rifimipic:in 
Rifcin 450 mg Rifampicin 
Be-Tabs Isoniazid 100 Isoniaiid 
Pyrazide Pyrazinamide 
Purderal P 400 mg tablets Ethambutol 
the formulations. All formulations were then 
from light at a temperature of approxi, 
marcly 4"C and in a limited-access area. 
Preference for screening was in the order of 
drus, three-drug and two-drug comhin:ttions, r:tfl-
domised imernally per group. 
Dic'eQUlv.ale,nce studies 
A two-period randomised cross-over study design was 
conducted, utilising at 18 healthy male vo!unree!-"s. 
Strict inclusion and exclusion criteria were applied.!1 
Drugs were administered as a single bolus with 200 ml 
of t~lP water in therapeutic doses after an overnight 
Blood s:lmples were into hep:lrinised tubes 
at 0, 1,2, 4, 6, 8 and 12 hours after each drug admin-
istration an in-dwelling venous cannub. Urine 
s;lmplcs were from 0-4 hours and from 4-8 
hours (data not presented in this mOlnuscript) .. 
studies 
Number Total 
120 5 tablets 600 
50 250 
300 1500 
2 tablets 450 
300 
1000 
225 2 tablets 450 
150 300 
750 1500 
400 800 
150 4 tablets 600 
100 400 
500 2000 
267 1068 
300 2 capsules 600 
150 300 
I 4 600 
lOP 4~.o 
,". 
2 capsules 4$0. 
300 
1500 
120 5 tablets 60.0 
80 400 
250 1250 
150 4 capsules 600 
100 400 
225 2 tablets 450 
1·50' 300 
750 1500 
Rolab (Ply) ltd 600 
Rolab (F'ty) ltd 450 
8e-Tab, Pharmaceuticals (Ply) ltd 100 
ltd 500 
Ltd 400 
Three hours following ;ldministration, a light 
liUl.llI.IUnllliC:U breakfast was Lunch was served 
5 h6urs after drug :idministr:ltion, and thereafter fluid 
w'as allowed ad libitum. . 
After a one washout period, volun-
teers the alternative study in 
exactly the same (Table 1). 
Drug methodology 
Plasma rifampicin conceritrations were determined 
usirig a validated high performance liquid chromato-
graphic (HPLC) assay technique at the Department of 
Pharmacology, University of Cape Town. The assay 
procedure was developed in-house.!2 
Quantitation of the chromatograms used the peak 
area method. The inter-day and intra-day coefficient 
of variation for the assays was <6%, while the limit 
of quantitation (LQ) for rifampicin was 0.05 ILs/ml.1l . 
./' 
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The d:lt3 from the bioequivnl~nce studies were sllb~ 
to non-compartmental analysis. Concenmuion-
time curves were plotted for each of 
From these plots, c...u was taken as the hio'h"'~r 
concentration measured. 
The area under the- plasma concentrluion-time 
, curve until 8 hours and until last time measured, 
.i.e., 12 hours (AUCo-lI and for rif:lmpicin). 
waS determined by the (linear/log~rithmic) trapezoi· 
dalrule. 
parameters were t~ analysis of 
variance (ANOVA) after log transformation of the 
data and' formulation. subject, sequence and 
period as the treatment effects. ~ 
90% intervals (90% were computed 
for the ratio of teslir'eference using both paramere~ic 
merhods (based on the ANOVA) and non-p:trametric 
methods.'" Bioequivnlence waS declared if the 90%, 
for the test/reference ratio IllY completely in the 
range 80-125%. In addition. for the paramerricannl-
ysis the, null hypqtheses foi;' ~oth the two one~sided t 
testsIS,hitd,be rejected at'ihe p,:< 0.05 level before 
bioeqpivalericecould be declare,d. 
Statistical annlysesconducred using \'(lin-
No,~ii~ 'Pro Version 1.5 (Scientific Inc.). 
.and Excel 
RESULTS 
The composition of the 10 rifnmpicin-containing FOCs 
and that of the reference formulations is recorded in 
'Table 1. There were three two-drug combinations 
(formulntions p. 0 and Q). five three-drug combin:t-
.' tiohs(for~ul:ltiotl'S J, ~landF). 3f1d. [\Vo follt-
drug combinations (forrriui:uions E ::tnd 
The rifar.npicira .concenmnion versus tim~ p ["oflles 
for the 10 formulations rehuive [0 the reference for-
mulation are iIl.usrrared in Figures 1-10. Formula-
tions N, D and J were the,only three formuJ-arions 
that were found to be, bioequivaJent (Table 2). 
All of the seven formulations rhat were not found 
to be bioequivalent:.to the reference formuhlrion dis-
played 90% CIs that in¢luded values th:u ,vere below 
80%. In rhe case of formulations C nndF. al190% CIs 
"vere below 8'0%. .. . . 
Therc'wasverrgo04 agreement betweenrne para-
metric and, noh~pnramei:ricst;1tistic:d analyses con-
t1l1rr .. ,t1 on this Th~re was also good agreement 
between the parameters ofAUCo..s and AUCo-I2_ 
DISCUSSION AND CONCLUSIONS 
Seven ohhe 10 rifampiCin-containing formub-
rions inve.sEigart:~. inthi~srl.ldy ~yere flot found. • to 
. ,bioequi~~,erit).~t:cotoingto intem::"~ionany accepted 
. criteria ftfrbioequivafen'ce.Thisraisesc.f!use for con-
. thn~·these fo~trnulatic)lis clIrrenrirllse in 
. cQntrprprqgramm~s. . . .. 
. It is therefore. that problem ofpobr bio-
availability ofrifnmpicin from FOCs, first revealed by 
Acocella6 and suspected in India by Fox,S is still seri-
ous. Ho";vever, although the probability of poor bio-
avail:tbility frofll FDCs has ~een suggested ove.l" the 
past decadf7' this is the first study to comprehenSively 
document th~ problem using a post-marketing sur-
., ......... ~,. .. strntegy'and n randomised cross-over 
Formulation N 
AUC(fdc)/AUC(ref) '" 102 "10 
90"loCI: 91 -113 "10 
I 
u_. __ ...... f' 
t 10 +--......,"" 
E 
S 
a: 
o 2 4 
.. __ ....... " ... "._----- -' '---' 
6 8 10 
Time (hour) 
j 
-....... ---... ..:.~ ... 
12 
-e- FDC 
... ReI 
Figure 1 Graph of mean log rifampicin concentration <lkglml) versus time (hours) in 19 healthy volunteers. The test formulation N 
(~). a ~hree·drug fixed-dose combination anti-tuberculosis formulation containing rifampicin (120 mg). isoniazid (SO mg) and pyra-
zmamlde (300 mg) and the reference formulations (c} were administered in equivalent doses in a randomised cross-over with 
a t week washout period. . 
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· Formulation c··· 
AUC(fdc)I~UC(ref):: 69 % 
gOy.cl :61 ·77 0/. 
4 6 8 10 12 
Time (hour) 
, 
-9- FCC 
-- ~ef 
Figure 2 of mean log rifampicin concentration (lLglml) versus time (hour) in 22 healthy volunteers. The test Formulation C 
(0), a three-drug fixed-dose combination anti-tuberculosis formulation (225 mg). isoniazid (150 mg) and pyr-
azinamide (500 mg) and the reference formulations (0) were administered in in a randomised with 
a 1 week washout period. 
Figure 3 Graph of mean log rifampicin concentration (fJ.glml) versus time (hour) in 20 healthy volunteers. The test Formulation E 
(.J). a four-drug fixed-dose combination anti-tuberculosis formulation containing rifampicin (225 isoniazid (150 mg). pyrazina-
mide (750 mg) and ethambutol (400mg) and the reference formulations (e) were administered in doses in a randomised 
cross-over study with a 1 week washout period. 
Formulation H 
AUC(fdc)/AUC(ref) .. 83 % 
90% CI : 76 • 92 % 
.. _ .. _-_.-.. , .. - .... ' .... _ ............. -..... ,~ ........ ----,--'--. _ •.... _----._--
0.1 
o 2 6 
Time (hour) 
8 10 12 
+FDC 
-- Ref 
Figure 4 Graph of mean rifampicin concentration (fJ.glml) versus time (hour) in 21 healthy volunteers. The test formulation H 
(0). a four-drug fixed· dose combination anti-tuberculosis formulation containing rifampicin (150 mg). isoniazid (100 
mide (500 mg) and ethambutol (267 mg) and the reference formulations (0) were administered in equivalent doses in a frinnnrni<;,,'n 
cross-over study with a 1 week washout period. 
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Figure S Graph of mean log rifampicin concentration (J.!.g}n;1) versus time (hour) in 22 healthy volunteers. The test Formulation P 
(0), a two-drug fixed-dose combination anti-tuberculosis formulation containing rifampiCin (300 mg) and isoniazid (1 SO mg) and the 
reference formulations (0) were administered in equivalent doses in a randomised cross-over study with a 1 week washout period. 
Formulation D 
AUC(fdc)IAUC(ref) = 97 % 
90% CI: U ,.112 % 
10~======~======~=======+======~===.-=~~.==~====~ 
._--+-- ------ -.. 
o 2 4 6 
Time (hour) 
1() 
-.e-FOC 
.",- Ref 
12 
Figure 6 Graph of mean log rifampicin concentration (I-Lglml) versus time (hour) in 20 healthy volunteers. The test formulation 0 
(0), a two-drug fixed-dose C<lmbinaUon anti-tuberculosis formulation containing rifampicin (1 SO mg) and isoniazid (laO mg)andthe 
reference formulations (0) were administered in equivalent doses in a randomised Cfoss-over study with a 1 week washout period. 
Formulation J 
AUC(fdc)IAUC(ref) = 106 % 
" 90% CI: 98 -116 -I. 
0.1 +----------4----------+---------~----------~----------~--------~ 
o 2 6 
Time (hour) 
10 12 
--e- foe 
-- Ref 
Figure 7 Graph of mean log rifampicin concentration (I-Lglml) versus time (hour) in 22 healthy volunteers. The test Formulation J 
(c). a three.drug fixed· dose combination anti-tuberculosis formulation containing rifampicin (225 m9), isoniazid (150 mg) and pyr-
azinamide (150 m9) and the reference formulations (0) were administered in equivalent doses in a randomised cross-over study with 
a 1 week washout period. 
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Formulation M 
AUC(fdc)/AUC(refl = 81 % 
90% CI : 72 - 91 % 
6 
Time (hour) 
-e- FOC 
-e- Ref 
10 12 
Figure 8 of mean log rifampicin concentration (~g/ml) versus time (hour) in 21 healthy volunteers. The test Formulation M 
(e), a three-drug fixed-dose combination anti-tuberculosis formulation containing (120 mg). isoniazid (80 mg) and pyra-
zinamide (250 mg) and the reference formulations (0) were administered in equivalent in a randomised cross-over study with 
a 1 week washout period. 
o 2 
Formulation Q 
AUC(fdc)fAUC{ref} ::: 68 % 
90% CI : 58 - 80 % 
Time (hour) 
-e- FOC 
-e- Ref 
8 10 12 
9 of mean log rifampicin concentration (Il.g/ml) versus time (hour) in 21 healthy volunteers. The test Formulation Q 
a two-drug combination anti-tuberculosis formulation containing rifampicin (1 SO m9) and isoniazid (100 mg) and the 
reference formulations (0) were administered in equivalent in a randomised cross-over study with a 1 week washout period. 
0.1 
o 2 
Formul:ltion F 
AUC(fdc)/AUC(ref) = 70 0/0 
90% CI : 63 - 78 0/. 
-_._ ... _-_ • ..j -------- -_. _._--. 
6 
Time (hour) .. 
10 12 
-e- FOe 
..... Ref 
Figure 1 t) Graph of mean log rifampicin concentration (~gfml) versus time (hour) in 22 healthy volunteers. The test Formulation F 
(0). a three-drug fixed· dose combination anti-tuberculosis formulation containing (225 mg), isoniazid (1 SO mg) and 
pyraznamide (750 mg) and the reference formulations (0) were administered in equivalent in a randomised (foss-over study 
with a 1 week washout period. 
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therOlpeuticm,a~gin f>f~,f;:U:l1p!~i~ ~ttiy,ity; i,s; 
Hence nny reduction inbi9~v~ilt\ 9ilitY;;h~~,~er,i;'" 
implication~ Jor'b,o,t~;t~~(fi'tdiY!~:hl:ilpa't:i:e:n~" ~s ' 
well ;IS for l'I:\tiO!1~J tuberculps~{contri:>,1 pr6sr4iilmes 
due toporen'ti;lltreaimen'r,' faih.~i~tlrid the}e!~cfi()ll.~f , 
drug-resistant mutants. " , , "" '..' . 
The primarycrireii,:nt. used. for O1'ssessrnCl1t 
bioequivalence was the AUC~ ,as ' 
international regul:u:ory bQdies as , 
States Food 3T4d Drug Administrati.on: In study, a 
is re:ls$uring. 
-Iris. de::nly important to "' .... ~""..,,,l 
restricted screening protocol utilising six 'blood col- . 
leetioh timepoint.s was u.se~? II, With the ~on~et!9~ of 
an additional blood sample ~t 12hoQr~. In'vic\yof the 
'rel;tricted sampling at 'the tiirlC:9f th,e eSt'im~l:~d Cm:.~, 
ih'is'parameter \VaS considered t~ he .. oflesserjmpi;;r-
include other FDes at ' , . 
'unknb\~IJ;:bioavailability. Billl"1llUi1/:1 
notb'een ':1 ' ,. ..P.,i.,t· ..... ';,.,";.;~ 
<0, 
Formulation E MediatVinean. ; 'j5 76 '75 71 81 , 
n 20 90%:(1 . 62-90 65"':92 '6l$,;88 :6&"90' ·6g..96·, 
P<:';80 0.75 0.67. '.' . 0.44 
P-;" 125 <0,001 <0 .. 001 
, Formu!ati()n H Median/mean ' 84 80 "i2 83 
0'=21' 90%:(t1 71-93 74..:91 ' 7&-;92 
P"£'80 0.35 . ' "o.if 
,f, P>.125.· . <0:001 . <0.O!)1 
formulation P . Mediahimean 87 88 91 86 . 
n'" 22 90%(1 71-96 79-98 82-98 17-96 
P<80 0.3 0,15 0.16 
P> 125 <0.001 <0.001 <0.001 
Formulation 0 Median/mean 95 97 97 94 97 98 
n = 20 90%CI 80-t07 83-112 82-116 81-110 &4-112 82-117 
P<80 0.03 0,015 0,03 
P> 125 0.006 0.01 0.03 
Formulation J Median/mean 106 106 100 107 106 lOt 
n = 22 90%CI 9a-H6 97-116 90-112 98-11'6 98-116 90-114 
P<80 <0,001 <0~O01 <0.001 
P> 125 i~"':" 0.Q1 0.Q1 0.Q1 
Formulation M Median/mean 80 .78 73 82 81 76 
II '" 2 i 90%CI 11-93 72-91 b4-88 12-94 72-91 66-S6 
P<80 0,35 0.41 0.77 
P> 125 <0.001 <0.001 <0.001 
Formulation Q Median/mean 65 66 70 68 68 72 
n "" 21 90%(1 57-80 57-79 58-84 57-81 58-80: 59-87 
P< 80 q..94 0.95 0.82 
P> 125 <0,001 <0.001. <0.001 
Formulation F Median/mean 73 73 72 70 70 69 
n "" 22 90%(1 65-79 64-78 66-79 63-78 63-78 61-78 
P< 80 0.98 0.97 0.98 
P> 125 <0.001 <0.001 <0.001 
AUC == area under the curve; C ..... '" maximal serum concentration; 90%CI -= 
.' 
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formulations despite WHO/IUATLD . to. 
this effect, Instead, formulntions have been registered, 
on the strength of dissolution::and stability datil alone. 
The implications for TB comrol are 
extremely seriolls and warrant urgent attention. 
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